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ABSTRACT 
 
 
Blood coagulation requires the assembly of several membrane-bound 
protein complexes composed of regulatory and catalytic subunits.  The 
biomembranes involved in these reactions not only provide a platform for these 
procoagulant proteins, but can also affect their function.  Increased exposure of 
acidic phospholipids on the outer leaflet of the plasma membrane can 
dramatically modulate the catalytic efficiencies of such membrane-bound 
enzymes.  Under physiologic conditions, however, these phospholipids 
spontaneously cluster into a patchwork of membrane microdomains upon which 
membrane binding proteins may preferentially assemble.  As a result, the 
membrane composition surrounding these proteins is largely unknown.  Through 
the development and use of a nanometer-scale bilayer system that provides 
rigorous control of the phospholipid membrane environment, I investigated the 
role of phosphatidylserine, an acidic phospholipid, in the direct vicinity (within 
nanometers) of two critical membrane-bound procoagulant protein complexes 
and their respective natural substrates.  Here, I present how the assembly and 
function of the tissue factor·factor VIIa and factor Va·factor Xa complexes, the 
first and final cofactor·enzyme complexes of the blood clotting cascade, 
respectively, are mediated by changes in their immediate phospholipid 
environments. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 AN OVERVIEW OF BLOOD CLOTTING 
 
At the macromolecular level, blood clotting is a series of proteolytic events 
in which zymogens are converted into active proteases (Fig. 1.1).  This blood 
coagulation cascade requires the assembly of several phospholipid membrane-
bound protein complexes that are made of a pair of regulatory and catalytic 
protein subunits.  Blood clotting is initiated when a nonvascular integral 
membrane protein, tissue factor (TF), is exposed to the bloodstream.  Once 
exposed to plasma, TF can complex with and significantly enhance the 
enzymatic activity of the serine protease factor VIIa (fVIIa).  The resulting TF·VIIa 
complex then activates coagulation factors IX and X (fIX, fX, respectively) via the 
extrinsic pathway of blood coagulation.  A series of proteolytic events ultimately 
lead to fibrin clot formation and platelet activation [1,2]. 
 
1.2 TISSUE FACTOR IS THE ACTIVATOR OF THE BLOOD 
COAGULATION CASCADE 
 
TF is a small transmembrane cell surface protein responsible for the 
physiologic triggering of the blood coagulation cascade in normal hemostasis and 
the pathophysiologic activator of clotting in a variety of thrombotic diseases.  TF 
initiates blood coagulation by interacting with the plasma protein, fVIIa.  fVIIa has 
limited enzymatic activity on its own, but once bound to its protein cofactor, TF, 
its activity is tremendously enhanced [3].  The resulting TF·VIIa complex then 
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activates fIX and fX via limited proteolysis, ultimately leading to fibrin clot 
formation and platelet activation.  TF is constitutively expressed on many cell 
types that are not in contact with blood, especially on the adventitial cells 
surrounding most blood vessels.  It can be thought of as forming a functional 
hemostatic envelope around the vasculature to prevent excessive bleeding.  TF 
is also a component of atherosclerotic plaques, and TF-mediated coagulation 
following plaque disruption is thought to trigger thrombus formation in myocardial 
infarction and ischemic stroke [2]. 
TF can be found in either a 261 or a 263 amino acid form in the body with 
nearly equal abundance.  These two species have a molecular weight of 29,447 
or 29,593 Da respectively [1], but have an apparent molecular weight of 
approximately 45,000 Da when analyzed by sodium dodecyl sulfate (SDS) gel 
electrophoresis due to post-translational glycosylation [4].  Glycosylation has 
been found unnecessary for procoagulant activity and fully active, recombinant 
TF is routinely produced in bacteria.  The structure of TF protein consists of an 
extracellular domain, a single transmembrane domain, and a short cytoplasmic 
tail which respectively participate in fVII(a) binding, cell membrane anchoring, 
and an uncertain function (Fig. 1.2).  Deletion of the cytoplasmic tail has no 
evident effect on procoagulant activity [5], but is speculated to play a role in cell 
signaling events [6].  TF must be incorporated into a membrane bilayer that 
includes net negatively-charged phospholipids, in particular phosphatidylserine 
(PS), for maximal procoagulant activity [7,8].  This reliance on phospholipids is 
3 
 
evident with recombinant forms of TF that lack a transmembrane domain (soluble 
TF or sTF).  Although sTF is able to bind fVIIa, the resulting sTF·VIIa complex 
exhibits dramatically decreased rates of substrate activation [9]. 
The mechanism(s) by which TF enhances the activity of fVIIa, and the role 
of specific phospholipids in enhancing catalysis by TF·VIIa are not fully 
understood.  It is believed that membrane-bound TF: 1) provides a receptor-like 
surface for binding its substrates [10,11], 2) allosterically activates fVIIa via 
induction of conformational change within the fVIIa active site [7], and 3) rests on 
a phospholipid surface that is also conducive to binding substrates [8], effectively 
increasing the concentration of substrates within the vicinity of TF.  The 
combined result of these interactions conferred by TF increases the activity of 
fVIIa many thousand-fold [10-12]. 
 
1.3 VITAMIN K-DEPENDENT PROTEINS OF BLOOD CLOTTING BIND 
MEMBRANES VIA γ-CARBOXYGLUTAMIC ACID DOMAINS 
 
Many blood coagulation proteins such as prothrombin, fVII, factor IX and 
fXa belong to a highly homologous family of vitamin K-dependent proteins (Fig. 
1.2). Vitamin K-dependent proteins are so-named because certain N-terminal Glu 
residues in these proteins are post-translationally modified into γ-
carboxyglutamic acid (Gla) residues via a vitamin K-dependent carboxylation 
reaction [13].  In the presence of Ca2+, this Gla-containing domain (Gla domain) 
enables these plasma proteins to reversibly bind certain phospholipid 
membranes [14,15]. These proteins are predominantly synthesized in the liver 
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and are first released as zymogens into the bloodstream.  They are then 
proteolytically cleaved into their active, “a”, forms under certain physiologic and 
pathophysiologic conditions.  The half-lives of the activated forms, however, last 
merely seconds due to the presence of many protease inhibitors in the 
circulation.  fVIIa, on the other hand has limited reactively with these compounds 
and can persist in plasma for hours [16]. 
These serine proteases demonstrate trypsin-like homology via the Ser-
His-Asp catalytic triad.  Unlike more canonical serine endopeptidases like trypsin 
and elastase, however, these active blood coagulation proteases require a 
suitable phospholipid membrane, Ca2+ and a protein cofactor for optimal activity.  
For example, fVII is the zymogen precursor of fVIIa, and fVIIa complexes with TF 
in the presence of phospholipids and Ca2+ to make TF·VIIa, a highly active 
protein cofactor·enzyme complex.   
 
1.3.1 The Structure and Function of Factors VII and VIIa 
 
fVII is a 416 amino acid glycoprotein with a molecular weight of 50,000 Da 
[17].  This zymogen is composed of two epidermal growth factor (EGF)-like 
domains, a serine protease precursor domain and a Gla domain (Fig. 1.2).  
Within its Gla domain, 10 γ-carboxyglutamatic acid residues are present [18].  
The plasma concentration of fVII is approximately 10 nM [17,19].  Upon limited 
proteolysis, fVII is converted to an activated serine protease called fVIIa.  The 
conversion of fVII to fVIIa is due to cleavage of a single peptide bond, Arg152-Ile, 
and can be accomplished by several proteases such as thrombin, fIXa, fXa, fXIIa 
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and TF complexed with fVIIa itself [20-22].  Unlike other circulating activated 
serine proteases, fVIIa has a relatively long plasma half-life [16].  As such, when 
TF is exposed, the trace amounts of fVIIa that are present in the bloodstream are 
thought to prime the blood clotting cascade [23].  fVIIa has very limited proteolytic 
activity on its own, but when complexed with TF, Ca2+ and a suitable 
phospholipid membrane, its ability to activate fIX and fX increases substantially 
[3]. 
 
1.3.2 The Structure and Function of Factors X and Xa 
 
fX is a substrate for the TF·VIIa complex.  It is a 488 amino acid 
glycoprotein with a molecular weight of 56,000 Da [17].  This zymogen is 
composed of two EGF-like domains, a serine protease precursor domain and a 
Gla domain (Fig. 1.2).  It has 11 γ-carboxyglutamatic acid residues that are 
present in its Gla domain [24], and the plasma concentration of fX is 
approximately 200 nM [17,25].  The conversion of fX to its activated form, fXa, is 
due to a cleavage at Arg194-Ile, catalyzed by either TF·VIIa or the factor 
VIIIa·factor IXa complex [26].  fXa combines with its protein cofactor factor Va 
(fVa) to form the Va·Xa complex, which is responsible for catalyzing the 
conversion of prothrombin to thrombin. 
 
1.3.3 The Structure and Function of Prothrombin 
 
Prothrombin, also known as factor II, is a 579 amino acid glycoprotein with 
a molecular weight of 72,000 Da [17].  This zymogen is composed of two kringle 
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structures, a serine protease precursor domain and a Gla domain [27].  Ten γ-
carboxyglutamatic acid residues are present in its Gla domain, and the plasma 
concentration of prothrombin is between 1 and 2 µM [17,28].  Prothrombin is 
converted by the Va·Xa complex to its major product, α-thrombin (thrombin), 
through sequential proteolytic cleavage at two sites, Arg284-Thr and Arg320-Ile 
(Fig. 1.2).  Cleavage at the Arg320-Ile activates the protease domain of 
prothrombin.  Alternatively, cleavage at Arg284-Thr removes the Gla domain 
from the protein rendering it soluble.  Depending on the order of cleavage of 
these two bonds, two possible intermediates, meizothrombin, or prethrombin 2, 
may be formed [29].  Meizothrombin is the predominant or possibly only 
physiologically-relevant intermediate formed from the Va·Xa complex conversion 
of prothrombin to thrombin [30]; it is transiently formed when cleavage at Arg320-
Ile precedes that of Arg284-Thr in the presence of a proper membrane surface. 
 
1.4 THE STRUCTURE AND FUNCTION OF FACTORS V AND Va 
 
Factor V (fV) is the procofactor form of fVa (Fig. 1.4).  As opposed to the 
Gla domain-containing proteins discussed above, the membrane binding 
domains of fV most closely resemble factor VIII and to a lesser extent, 
ceruloplasmin or discoidin I [31-33].  fV is a 2,196 amino acid protein with a 
molecular weight of 330,000 Da [17].  It has a plasma concentration of 
approximately 30 nM [17,25], of which 20 to 25% are found in α-granules of 
platelets [34].  It is organized into 6 domains: A1-A2-B-A3-C1-C2 [32].  In order to 
function as a cofactor, fV is proteolytically cleaved by thrombin at residues 
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Arg709-Ser, Arg1018-Thr, and Arg1545-Ser [32].  As a result, the B domain is 
removed and its activated form, fVa, composed of a light and heavy chain, is 
formed.  The heavy chain (94,000 Da) and light chain (74,000 Da) of fVa are 
noncovalently linked through a Ca2+ bridge [35].  Prothrombin interacts with the 
light chain, and fXa interacts with both the heavy and light chains.  The heavy 
chain confers most of the cofactor activity and the light chain (A3-C1-C2) 
constitutes the primary membrane binding domain for fVa [36,37].  Within the 
light chain, the C1 and C2 domains (C domains) are generally regarded as the 
primary membrane binding domains of fVa [38-41].  The exact contribution of the 
A3 domain to phospholipid binding is still relatively unknown.  This domain has 
been recently modeled resting away from the membrane and upon the C 
domains, but other studies have also shown it interacting with phospholipids 
[39,42].  The fVa molecule binds membranes via electrostatic and hydrophobic 
interactions through an incompletely understood mechanism [37,43,44].  Under 
experimental conditions, fVa is able bind membranes composed of pure PC, 
however the physiological relevance of this is questionable as the reported Kd for 
this is at least 2 orders of magnitude beyond the reported plasma concentration 
of fVa [34,45].  As such, to achieve binding at physiological levels, a minimum 
amount of PS molecules is simply required. 
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1.5 Va·Xa IS THE FINAL COFACTOR·PROTEASE COMPLEX OF BLOOD 
COAGULATION 
 
The Va·Xa complex (prothrombinase complex) is the physiological catalyst 
responsible for the conversion of prothrombin to thrombin [46,47].  This complex 
is composed of a serine protease, fXa, and its protein cofactor, fVa, assembled 
upon a membrane surface containing anionic phospholipids and Ca2+ [48,49].  
Membrane-bound fVa is thought to provide an anchor for both its companion 
protease, fXa, and its substrate, prothrombin [35].  Studies using liposomes and 
other model membranes have shown that anionic phospholipids are required for 
optimal prothrombinase activity, with PS playing the most active role [50,51].  
Unfortunately, the mechanisms by which PS enhances the enzymatic activity of 
prothrombinase – or any other protease-cofactor complex in blood clotting – are 
not fully understood. 
 
1.6 THROMBIN PLAYS A CENTRAL ROLE IN HEMOSTASIS 
 
 Thrombin, or α-thrombin, is a soluble serine protease derived from the 
Va·Xa-catalyzed cleavage of prothrombin.  It has a molecular weight of 36,000 
Da and plays a central role in many physiological processes involving the overall 
maintenance of blood coagulation.  These processes include, but are not limited 
to, the activation of various zymogens and cofactors, the activation of platelets 
and the formation of fibrin from fibrinogen [35].  This fibrin clot is the end-result of 
the blood coagulation cascade and is further stabilized through the actions of 
activated factor XIII (fXIIIa).  fXIIIa is a transglutaminase that catalyzes covalent 
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bond formation between lysine and glutamine residues on fibrin that effectively 
cross-links and strengthens the fibrin clot.  In the laboratory, preparations of 
thrombin are susceptible to degradation via contaminating proteases (possibly 
including, thrombin itself).  These degraded forms of thrombin have relatively 
distinct cleavages patterns.  In general, these so-called β and γ-thrombins have 
limited activity towards fibrinogen and other natural substrates [52]. 
 
1.7 PHOSPHOLIPID MEMBRANES ARE THE SITES OF BLOOD 
CLOTTING REACTIONS 
 
Cell surfaces such as activated platelets, monocytes and damaged 
endothelial cells constitute the membrane surfaces for blood clotting reactions, in 
vivo [51].  On a resting cell or unactivated platelet surface, PS and other 
aminophospholipids are normally sequestered within plasma membranes and 
away from the circulation, while choline phospholipids such as 
phosphatidylcholine (PC) are predominantly on the outer leaflet [48,53].  Upon 
cell damage or induction of other stressors, anionic lipids such as PS, are 
scrambled onto the outer leaflet.  The end result of this process ultimately 
induces many events in the body, including blood clotting. 
To great effect, many in vitro studies involving blood clotting complexes 
have used mixtures of net neutral and anionic phospholipids in liposomes as 
model membrane systems that recapitulate the stimulatory affects of their natural 
counterparts [50,51].  Notably, PS is accepted as the most effective surface in 
supporting catalysis [51].  Conventional phospholipid preparations containing 
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high concentrations of PS, however, are susceptible to fusion or collapse, in the 
presence of physiological amounts of Ca2+ [54].  As such, mixtures of PS and the 
net neutral phospholipid, PC (together as PCPS) are routinely used in 
experiments. 
In the presence of Ca2+ or membrane binding proteins, even simple 
membranes composed of binary mixtures of net-anionic and neutral 
phospholipids are capable of forming microdomains rich in anionic phospholipids.  
Experiments with giant unilaminellar vesicles, for example, have shown that 
anionic phospholipids are capable of migrating across relatively long distances 
and clustering into large microdomains [55,56].  Heterogeneous domain 
formation may, in turn, substantially change the local surface properties on the 
membrane surface.  As a result, the actual phospholipid microenvironment on 
mixed-phospholipid membranes may vary dramatically from the average 
composition of the bulk membrane.  Little is known, however, about how local 
membrane microdomain composition affects the assembly and function of 
procoagulant protein complexes. 
TF is an integral membrane protein and must be incorporated into a suitable 
membrane surface for optimal function.  Most methods for inserting TF into 
liposomes (TF-liposomes) involve the formation of mixed micelles containing 
detergent, phospholipids and TF, taking advantage of the natural ability of 
phospholipids to self-assemble into bilayer structures upon detergent removal.  
Although our laboratory has recently developed a rapid method by which TF can 
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be incorporated into liposomes [57], some of the traditional problems associated 
with classic TF relipidation techniques still remain, such as: 1) random orientation 
of TF in the liposomes, with roughly half of the molecules facing into the lumen; 
2) heterogeneity in TF-liposome size distribution; and 3) inconsistent loading of 
TF from one liposome to another. 
An additional difficulty in using TF-liposomes to study the function of the 
TF·VIIa complex is that both the enzyme (fVIIa) and the substrates bind 
reversibly to the phospholipid surface independent of their interactions with TF.  
As such, there is a large excess of protein binding sites on the liposome surface 
compared with the surface density of TF.  This makes it technically difficult to 
distinguish between protein-phospholipid and protein-protein interactions when 
studying the assembly and function of protease-cofactor pairs. 
 
1.8 NANODISCS PROVIDE RIGOROUS CONTROL OF THE LIPID 
NANOENVIRONMENT SURROUNDING PROCOAGULANT PROTEINS 
 
In the present study, we used nanometer-scale phospholipid bilayers 
(Nanodiscs) of defined size and phospholipid composition as the experimental 
membrane surface upon which to assemble and study the components of the 
blood coagulation cascade (Fig. 1.5).  Nanodiscs are water-soluble bilayers 
encircled and stabilized by an amphipathic helical protein termed membrane 
scaffold protein (MSP). The nanobilayers within Nanodiscs are monodisperse 
and exhibit lipid fluidity comparable to liposomes [58,59]. Nanodiscs self-
assemble from mixtures of phospholipids and MSP, to form stabilized nanoscale 
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bilayers whose lipid composition is under strict experimental control.  Newer-
generation Nanodiscs have been developed using MSPs that have been 
systematically elongated or truncated to yield stabilized, monodisperse 
phospholipid bilayers ranging from about 8 to 15 nm in diameter [60]. By 
assembling the constituent proteins of certain blood clotting complexes on these 
nanobilayers, we can circumvent the long-range recruitment of anionic 
phospholipids that occurs in larger phospholipid systems such as liposomes.  
This affords us complete control over the composition of the membrane 
nanoenvironment immediately surrounding these complexes.  
 
1.9 BLOOD COAGULATION ON NANOSCALE MEMBRANE SURFACES 
 
Blood coagulation requires the assembly of several membrane-bound 
protein complexes, each composed of both regulatory and catalytic protein 
subunits.  In addition to providing a platform for assembly, biological membranes 
also modulate the catalytic activity of serine protease-cofactor complexes in 
blood clotting [51].  Studies using liposomes and other model membranes have 
shown that anionic phospholipids are required for optimal procoagulant activity, 
with PS being the most active [50,51].  Unfortunately, the mechanisms by which 
PS enhances the enzymatic activity of protease-cofactor complexes in blood 
clotting are not fully understood. 
I hypothesize that blood clotting protease-cofactor complexes partition into 
discrete membrane microdomains of very high PS content.  Studies of giant 
unilaminellar vesicles composed of mixtures of anionic and neutral phospholipids 
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have shown that plasma concentrations of Ca2+ can induce anionic phospholipids 
to move over relatively long distances to cluster into anionic phospholipid-rich 
membrane domains.  Clustering of anionic phospholipids was even more 
dramatic when vesicles were treated with combinations of Ca2+ and proteins 
known to bind to anionic phospholipids, such that the membrane-binding proteins 
co-clustered with anionic phospholipids [55,56].  It therefore seems likely that 
blood clotting reactions occur preferentially on membrane surfaces containing 
very high amounts of PS in the immediate vicinity, which may result from both 
Ca2+ and the PS-binding properties of the proteins themselves.  Unfortunately, 
when using even simple model membranes, it is very difficult to know the 
phospholipid composition immediately surrounding these membrane-bound 
complexes and their membrane-bound substrates.  For example, in the presence 
of plasma concentrations of Ca2+, liposomes composed of 20% PS and 80% PC 
are likely to segregate into a patchwork of microenvironments in which the local 
PS content at any given point may be considerably higher or lower than the 
average of 20%. Thus, local variations in the membrane nanoenvironment 
immediately surrounding these complexes may dramatically alter their catalytic 
efficiencies. When using liposomes or other model membranes, this parameter is 
typically not under experimental control. 
To address this problem, I have used nanometer-scale phospholipid 
bilayers (Nanodiscs) of defined size and phospholipid composition as the 
experimental membrane surface upon which to assemble and study the 
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components of two critical procoagulant complexes: TF·VIIa and 2) Va·Xa.  
These are the first and last membrane-dependent complexes in the coagulation 
cascade respectively.  By assembling the constituent proteins of these two 
complexes on nanoscale bilayers, the long-range recruitment of anionic 
phospholipids that occurs in larger phospholipid systems such as liposomes can 
be circumvented.  This affords complete control over the composition of the 
membrane nanoenvironment immediately surrounding (within nanometers) of 
these complexes.  This first chapter serves as a brief introduction to blood 
coagulation and the dynamic role of membrane micro- and even submicroscopic 
environments in shaping this process.  The second chapter of this thesis 
illustrates the assembly and characterization of Nanodiscs containing anionic 
phospholipids and then details the incorporation of TF into these structures.  
Using the same nanoscale system, the third chapter describes the assembly and 
function of the TF·VIIa complex, the initiator of the blood clotting cascade.  The 
fourth chapter then investigates the Va·Xa complex, the final phospholipid-
dependent complex of the blood coagulation system.  Finally, the fifth chapter will 
summarize and discuss the relevance of this project as it relates to the overall 
process of blood coagulation, as well as the potential clinical applications of this 
work. 
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1.10 FIGURES 
 
 
FIGURE 1.1 Simplified TF·VIIa coagulation pathway.  Blood coagulation is a 
series of proteolytic events where zymogens are converted into active proteases.  
TF·VIIa converts factor X to factor Xa.  Factor Xa complexes with factor Va to 
form Va·Xa.  Va·Xa converts prothrombin to thrombin.  Thrombin converts 
fibrinogen to fibrin, and factor XIIIa catalyzes the cross-linking of fibrin.  The two 
membrane-bound protein complexes depicted in this figure are made of protein 
cofactor·protease partners that require calcium ions (Ca2+) and phospholipids 
(PL) for maximal activity.
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FIGURE 1.2 Structure of the soluble TF·VIIa complex.  The crystal structure 
is on the left, and a cartoon is on the right.  The active site of factor VIIa is 
depicted toward (A) and away from (B) the viewer.  Depicted on factor VIIa is its 
serine protease domain (light gray) and its EGF and Gla domains (dark gray).  
The inhibitor (white) is in the active site of factor VIIa.  TF, with its labeled N and 
C termini, is also white.  The transmembrane domain and cytoplasmic tail of TF 
is not present in this figure, and the membrane surface would be located at the 
bottom of each complex.  (Generated from file “1DAN” from the Protein Data 
Bank, courtesy of James Morrissey.) 
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FIGURE 1.3 Vitamin K-dependent coagulation factors.  Schematic 
representations of γ-carboxyglutamic acid residue (Gla)-containing zymogens of 
blood clotting: factor VII, X and prothrombin.  Both factor VII and X contain 
epidermal growth factor (EGF)-like domains, while prothrombin has kringle 
domains.  Arrows indicate location of cleavage sites that are needed to generate 
an active serine protease. 
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FIGURE 1.4 Schematic representation of procofactor, factor V.  Labeled is 
the heavy chain (A1, A2) and the light chain (A3, C1, C2), held together by the B 
domain.  Arrows indicate location of cleavage sites needed to generate an active 
protein cofactor.  Complete cleavage by thrombin releases the B domain and 
produces activated factor V consisting of its heavy and light chains held 
noncovalently by Ca2+. 
 
 
 
 
 
 
 
 
 
 
FIGURE 1.5 Cartoon representation of a Nanodisc.  Nanodiscs are water-
soluble bilayers encircled and stabilized by an amphipathic helical protein termed 
membrane scaffold protein (MSP).  MSPs have been systematically elongated or 
truncated to yield stabilized, monodisperse phospholipid bilayers ranging from 
about 8 to 15 nm in diameter.  Depicted are phospholipids in light gray and MSPs 
in dark gray. 
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CHAPTER 2 
 
ASSEMBLY AND CHARACTERIZATION OF NANOSCALE BILAYERS 
 
 
2.1 BACKGROUND 
 
Blood coagulation requires the assembly of membrane-binding protein 
complexes composed of catalytic (protease) and regulatory subunits.  Cells such 
as platelets can dramatically mediate the catalytic efficiencies of such lipid-
binding proteases through increased exposure of PS on the outer leaflet of the 
plasma membrane.  In the presence of Ca2+, anionic phospholipids such as PS 
spontaneously cluster into membrane microdomains upon which phospholipid-
binding proteins may preferentially assemble.  Studies of giant unilamellar 
vesicles composed of mixtures of anionic and neutral phospholipids have shown 
that normal plasma concentrations of Ca2+ can induce such clustering of anionic 
phospholipids over relatively long distances.  This phenomenon was further 
attenuated by the addition of proteins known to bind to anionic phospholipids 
[1,2].   
It therefore seems likely that blood clotting reactions occur preferentially 
on membrane surfaces containing locally high PS content, which may result from 
both Ca2+ and the PS-binding properties of the proteins themselves.  
Unfortunately, even when using simple model membranes, it is very difficult to 
know the phospholipid composition immediately surrounding the membrane-
bound complexes of blood clotting.  In the presence of physiological plasma 
concentrations of Ca2+, for example, liposomes composed of 20% PS and 80% 
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PC are likely to segregate into a patchwork in which the local PS content at any 
given point may be considerably higher or lower than the average of 20%. Thus, 
local variations in the membrane nanoenvironment immediately surrounding 
blood coagulation proteins may profoundly alter their functions. When using 
liposomes or other model membranes, this parameter is typically not under 
experimental control. 
I approached this problem by using a unique system of stable nanoscale 
phospholipid bilayers referred to as Nanodiscs as a platform for studying 
membrane-protein interactions [3].  Water-soluble Nanodiscs are produced by a 
self-assembly process resulting in a submicroscopic lipid bilayer encircled and 
stabilized by two copies of an amphipathic helical protein known as membrane 
scaffold protein (MSP).  MSPs have been systematically elongated or truncated 
to yield stabilized, monodisperse phospholipid bilayers ranging from about 8 to 
15 nm in diameter [4].  This self-assembly process is reproducible and efficient, 
yielding homogeneous preparations of supported lipid bilayers that are extremely 
stable and exhibit lipid fluidity comparable to liposomes [5,6].  Moreover, 
heterologous membrane-spanning proteins can also be incorporated efficiently 
into these supported nanobilayers [7,8].  Unlike liposomes and most other model 
membrane systems, the phospholipid bilayers in Nanodiscs cannot undergo 
long-range Ca2+-induced reorganization of PS into regions of locally high PS 
content, which allows us to define the membrane composition immediately under 
and surrounding procoagulant proteins.   
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The assembly and characterization of 7.7 nm-diameter bilayer Nanodiscs 
containing net-neutral phospholipids have been firmly established by Stephen 
Sligar and his laboratory [9-12].  However, because blood clotting reactions occur 
preferentially in the presence of anionic phospholipids, bilayers containing just 
net neutral phospholipids are not ideal for the study of procoagulant proteins.  
Therefore, before conducting detailed studies with these proteins on Nanodiscs, 
it was necessary to assemble and characterize Nanodiscs containing PS in their 
membranes.  Another consideration is that blood coagulation is initiated by TF, 
an integral membrane protein that functions optimally when embedded within a 
bilayer containing PS.  As such, it was also necessary to integrate TF within a 
Nanodisc bilayer enriched with PS.  This chapter therefore focuses on defining 
the Nanodisc system: its assembly, bilayer composition and aggregation state in 
the presence of physiological concentrations of Ca2+.  Finally, this chapter will 
also discuss the incorporation and characterization of active TF within the 
Nanodisc system. 
 
2.2 EXPERIMENTAL PROCEDURES 
 
2.2.1 Materials 
 
PC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), PS (1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphoserine) and the lipid extruder were from Avanti Polar 
Lipids (Alabaster, AL).  The molecular weights of PC and PS are 760 and 784 
Da.  Recombinant human TF, sTF and Nanodisc membrane scaffold proteins, 
MSP1D1 and MSP1E3D1 were expressed in Esherichia coli and purified as 
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previously described [13-15].  The molecular weights of MSP1D1 and 
MSP1D1E3 are 24.7 kD and 32.6 kDa respectively.  
 
2.2.2 Preparation of Liposomes Containing Phosphatidylserine 
 
Liposomes of varying PS content (with the balance being PC) were 
prepared by membrane extrusion. Briefly, mixtures of PC and PS (PCPS) in 
chloroform were dried under nitrogen and placed under vacuum to ensure 
complete solvent removal. The lipids were resuspended in TBS (50 mM Tris-HCl, 
150 mM NaCl, 0.01% NaN3, pH 7.4), subjected to 10 freeze-thaw cycles, and 
then extruded at least 10 times through two track-etched polycarbonate 
membranes (100 nm pores) using a double-syringe lipid extruder. This technique 
produces unilamellar vesicles with a mean diameter of approximately 80 nm [16]. 
Considering that the surface area of a PC headgroup is 0.7 nm2 [17], an 80 nm-
diameter liposome is calculated to comprise roughly 22,500 phospholipid 
molecules per leaflet. 
 
2.2.3 Preparation of Nanodiscs Containing Phosphatidylserine 
 
Nanodiscs containing 7.7 nm-diameter bilayers of varying PCPS content 
were prepared using sodium deoxycholate as the detergent.  Briefly, PC and PS 
(5.2 mM total phospholipid) were dissolved in 10.4 mM sodium deoxycholate in 
TBS, after which MSP and TF were added to yield phospholipid:MSP molar ratios 
ranging from 65:1 to 70:1.  Deoxycholate was subsequently removed using 
adsorbent polystyrene beads (Bio-Beads® SM-2;  Bio-Rad, Hercules, CA), and 
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the resulting self-assembled Nanodiscs were purified using a Superdex 200 HR 
30/10 size exclusion chromatography column as previously described [18].  Final 
ratios of phospholipid to MSP were quantified through a combination of inorganic 
phosphorus analysis for phospholipid [19,20] and A280 for MSP1D1, using an 
extinction coefficient of 21,000 M-1 cm-1.  To assess Nanodisc PCPS 
composition, the phospholipid content of purified 7.7 nm-diameter Nanodisc 
preparations were quantified by incorporating traces of 3H-PS during self-
assembly.  Scintillation counting and the total phospholipid content by inorganic 
phosphate analyses following complete oxidation was used to determine PS 
recovery. 
Nanodiscs containing 10.8 nm-diameter bilayers were prepared similarly, 
except MSP1E3D1, a larger variant of MSP1D1, was used [4]. Briefly, 
deoxycholate-solubilized mixtures of PCPS and MSP1E3D1 protein were 
prepared at a 120:1 molar ratio of phospholipid to MSP1E3D1.  Deoxycholate 
was subsequently removed using Bio-Beads® SM-2, and the resulting self-
assembled Nanodiscs were purified using size exclusion chromatography as 
before [18]. Final ratios of phospholipid to MSP were quantified through a 
combination of inorganic phosphorus analysis for phospholipid [19,20] and A280 
for MSP1E3D1 using an extinction coefficient of 29,400 M-1 cm-1. 
 
2.2.4 Reconstitution of Tissue Factor into Liposomes and Nanodiscs 
 
TF was incorporated into liposomes (TF-liposomes) as described [21], 
using sodium deoxycholate as the detergent.  Briefly, mixtures of PC and PS in 
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chloroform were dried under nitrogen and placed under vacuum to ensure 
complete solvent removal. The lipids and TF were resuspended in 15 mM 
deoxycholate in TBS.  Detergent was removed using Bio-Beads® SM-2.  This 
produces a solution of relipidated TF with a molar ratio of phospholipid:TF of 
approximately 8,700:1. 
TF was introduced into Nanodiscs as described for the incorporation of β2-
adrenergic receptors into Nanodiscs [7] with the following modifications:  Mixtures 
of PC and PS (5.2 mM total phospholipid) were dissolved in 10.4 mM sodium 
deoxycholate in TBS, after which MSP and TF were added to yield 
phospholipid:MSP molar ratios ranging from 65:1 to 70:1, and MSP:TF molar 
ratios of 20:1.  Detergent was removed using Bio-Beads® SM-2 and self-
assembled Nanodiscs were isolated using size exclusion chromatography.  Each 
Nanodisc contains two MSP proteins, this large excess of MSP to TF results in 
an average of one TF molecule per 10 Nanodiscs.  This was done in order to 
minimize the occurrence of more than one TF molecule per Nanodisc. 
 
2.2.5 Assessment of Nanodisc Aggregation in the Presence of  
Calcium Ions 
 
Nanodiscs containing 0 to 100% PS were diluted in TBS with or without 
2.5 mM CaCl2 and incubated for a minimum of 20 min.  This process was also 
performed on TF-Nanodiscs containing 75% PS.  The samples were then 
resolved by size exclusion chromatography on a Superdex 200 column 
monitored by A280.  Nanodiscs with 7.7 nm-diameter bilayers were also analyzed 
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by dynamic light scattering in which intensity autocorrelation functions of 
micromolar quantities of TF-free Nanodiscs in TBS with or without 2.5 mM CaCl2 
were quantified at ambient temperature using a Brookhaven Instruments BI-200 
SM goniometer with a Lexel model 95 argon-ion laser (514 nm) at a scattering 
angle of 90°.  A photomultiplier tube was used to measure light intensity, with 
signal processing by a BI-9000AT digital correlator.  Using the Siegert 
relationship, the intermediate scattering function, g, was determined from the 
measured intensity autocorrelation function, G(τ) = B(1 + f 2 [g(τ)]2 ), where B is 
the background intensity, f is an optical constant based on the measuring 
instrument, and τ is the decay time [22]. 
 
2.2.6 Assessment of Tissue Factor Content and Function within 
Nanodiscs 
 
Total TF concentrations in liposomes and Nanodiscs were determined by 
ELISA after detergent solubilization [21].  Concentrations of functional (available) 
TF in TF-liposomes and TF-Nanodiscs were determined enzymatically by titration 
with a fixed concentration of fVIIa [23].  With TF-Nanodiscs, TF concentrations 
measured by ELISA agreed with the results of fVIIa titrations within experimental 
error (not shown), indicating that essentially 100% of the TF molecules in TF-
Nanodiscs were functional.  With TF-liposomes, approximately 50 to 60% of the 
TF molecules measured by ELISA were available by fVIIa titration (not shown), 
attributable to some TF molecules facing the lumen of the liposomes.  TF 
concentrations are given throughout as the concentration of available TF. 
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The TF-Nanodisc assembly process described above produces a mixture 
of Nanodiscs: a species containing TF (TF-Nanodiscs), and a species without TF 
(TF-free Nanodiscs).  To demonstrate the presence of only one TF molecule per 
TF-Nanodisc, TF-Nanodiscs preparations were first purified from TF-free 
Nanodiscs by affinity chromatography using immobilized HPC4 antibody directed 
against an epitope tag at the N-terminus of TF, as previously described [13,24], 
but omitting the 1M NaCl wash step.  These enriched TF-Nanodiscs were 
reanalyzed with a size-exclusion column monitored by A280 to verify their stability 
and size.  Finally, the stoichiometries of TF and MSP in preparations of these 
enriched TF-Nanodiscs were then assessed via quantitative SDS PAGE. 
To determine if TF incorporated in Nanodiscs retained cofactor function, 
the ability of TF-Nanodiscs of varying PS composition (from 20 to 100 mol%) to 
accelerate the clotting of plasma was investigated.  The total phospholipid 
concentration was held constant at 50 µM and clot times were measured as a 
function of TF concentration.  Similarly, the clot times of TF-Nanodiscs were also 
compared with TF-liposomes and soluble TF (sTF), two commonly used 
preparations of TF.  For these preparations, the total phospholipid concentration 
was fixed at 50 µM using vesicles composed of 20% PS.  The relative abilities of 
these TF preparations to induce blood coagulation was determined through a 
standard prothrombin time (PT) clotting assay using a STart® 4 coagulometer 
(Diagnostica Stago, Parsippany, NJ) according to the manufacturerʼs instructions.  
Briefly, these TF preparations at fixed TF concentrations were added to citrated 
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pooled normal plasma.  Citrate inhibits blood coagulation due to its chelating 
properties, and an excess of calcium chloride was used to initiate clotting and the 
time of clot formation was measured.  These measurements were all performed 
at 37° C. 
 
2.3 RESULTS AND DISCUSSION 
 
2.3.1 The Phospholipid Composition of Nanodiscs can be Rigorously 
Controlled 
 
Nanodiscs and TF-Nanodiscs containing 7.7 nm-diameter bilayers were 
prepared using varying proportions of PC and PS, ranging from 0 to 100% PS.  
These Nanodisc preparations were monodisperse, contained a mean of 67 ± 1 
phospholipid molecules per leaflet and had final proportions of PC and PS that 
faithfully reflected the input PC/PS content (Fig. 2.1).  Likewise, Nanodiscs with 
10.8 nm-diameter bilayers were found to contain a mean of 120 ± 4 phospholipid 
molecules per leaflet as assessed by inorganic phosphorus content (for 
phospholipids) and A280 (for MSP; data not shown).  
In order to test the hypothesis that locally high PS content enhances blood 
coagulation protein function, we needed to prepare Nanodiscs containing very 
high mol% PS.  This can be highly problematic when preparing liposomes, since 
exposing liposomes with very high PS content to plasma concentrations of Ca2+ 
leads to their aggregation, fusion and/or collapse [25].  Accordingly, we 
investigated the aggregation state of Nanodiscs containing 0 to 100% PS.  In the 
absence of Ca2+, both size Nanodiscs – containing 0 to 100% PS – were 
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monodisperse as assessed by size exclusion chromatography or dynamic light 
scattering.  In buffered solutions containing 150 mM NaCl and 2.5 mM CaCl2, 
Nanodiscs with 7.7 nm-diameter bilayers containing 0 to 90 mol% PS were 
monodisperse as assessed by dynamic light scattering (Fig. 2.2, A and B) and 
gel filtration (not shown).  On the other hand, only 7.7 nm-diameter bilayer 
Nanodiscs containing 100% PS showed limited but detectable aggregation in the 
presence of Ca2+, but not in its absence (Fig. 2.2C).  Likewise, in the presence of 
2.5 mM Ca2+, we observed no detectable aggregation of Nanodiscs containing 
10.8 nm-diameter bilayers composed of 0-70 mol% PS (Fig. 2.3, A and B).  We 
did observe some aggregation when these larger Nanodiscs contained 90% PS 
(Fig. 2.3C).  Our experiments with Nanodiscs containing 10.8 nm-diameter 
bilayers in solution in the presence of calcium ions were therefore restricted to 
Nanodiscs containing 0 to 70% PS.  
 
2.3.2 Functional Tissue Factor can be Incorporated into Nanodiscs 
 
During the assembly of 7.7 nm-diameter bilayer TF-Nanodiscs, a twenty-
fold excess of MSP1D1 to TF was used in order to ensure that no more than one 
TF molecule inserted per Nanodisc.  This however, produced a mixture of 
Nanodiscs: a species with TF inserted (TF-Nanodiscs) and a species without TF 
(TF-free Nanodiscs).  For certain experiments, TF-Nanodiscs have been 
separated from TF-free Nanodiscs through immunoaffinity chromatography 
specific for an HPC4 affinity tag on the N-terminus of TF [13].  The HPC4 
antibody binds to this peptide epitope in a Ca2+-dependent manner and with very 
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high affinity, which allows for gentle elution of the tagged protein using EDTA.  
The presence of this epitope tag has no effect on TF procoagulant activity.  
Through this process, an enriched population of TF-Nanodiscs can be isolated.  
When reanalyzed on size-exclusion chromatography, these enriched TF-
Nanodiscs elute with a more symmetrical peak and with a Stokes diameter that is 
slightly larger than TF-free Nanodiscs (Fig. 2.4). 
The TF and MSP content of this enriched TF-Nanodisc preparation was 
also investigated via SDS-PAGE followed by Coomassie staining and 
densitometry (Fig. 2.5).  Analysis of the SDS-treated TF-Nanodisc fraction shows 
both MSP and TF running in the same lane.  When the densities of the bands are 
compared against known quantities of TF and MSP loaded on the same gel, a 
determination of 0.51 TF per MSP molecule was made.  Since Nanodiscs have 2 
MSP molecules, this corresponds to 1.02 TF molecules per TF-Nanodisc. 
To determine if TF in Nanodiscs remained functional, the ability of TF-
Nanodiscs of varying PS content to accelerate the clotting time of plasma was 
evaluated as a function of TF concentration (Fig. 2.6).  Analysis of a standard PT 
clotting test demonstrated that TF-Nanodiscs do indeed possess appreciable 
procoagulant activity, with the fastest clotting times occurring at 20% PS. 
The ability of TF-Nanodiscs to accelerate the coagulation of plasma was 
also judged against more conventional TF preparations.  Using a standard PT 
clotting test, the clotting times of TF-Nanodiscs were compared with TF-
liposomes and a mixture of sTF plus phospholipid vesicles as a function of TF 
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concentration (Fig. 2.7).  These TF preparations had a total phospholipid 
concentration of 50 µM, composed of 20% PS.  Results indicate that TF-
Nanodiscs have a procoagulant activity that is somewhat less pronounced when 
compared to TF-liposomes but considerably more pronounced when compared 
to sTF.  The slower clotting time of sTF underscores the importance of having a 
proper phospholipid membrane in the immediate vicinity of the TF molecule. 
It is of note that the PT clotting assay used in this experiment is reliant 
upon two membrane-bound protease·cofactor pairs of the blood coagulation 
cascade: TF·VIIa and Va·Xa.  Blood coagulation is initiated by TF·VIIa and the 
procoagulant activity induced by TF embedded in Nanodiscs indicates that the 
enzymatic ability of the TF·VIIa complex functions upon a 7.7 nm-diameter 
Nanodisc bilayer.  However, because of the presence of excess phospholipids, 
this assay cannot adequately address if the Va·Xa complex functions on the 
Nanodisc surface.  Understanding these events, therefore, require more detailed 
experiments and are discussed in the subsequent chapters. 
 
2.3.3 The Nanodisc System Allows Rigorous Control of the Local 
Membrane Nanoenvironment 
 
I have successfully produced nanometer-scale bilayers of defined size and 
PCPS compositions.  Nanodiscs with 7.7 nm-diameter bilayers were found to 
contain a mean of 67 ± 1 phospholipid molecules per leaflet and had final 
proportions of PC and PS that were faithfully preserved throughout the assembly 
process.  Likewise, Nanodiscs with 10.8 nm-diameter bilayers were found to 
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contain a mean of 120 ± 4 phospholipid molecules per leaflet.  Except for 
extreme circumstances, Nanodisc species containing PCPS bilayers are stable in 
physiological amounts of Ca2+.  Moreover, active membrane-bound TF has been 
successfully reconstituted into 7.7 nm-diameter Nanodiscs.  These TF-Nanodiscs 
have a stoichiometry of 1.02 TF molecules per Nanodisc and exhibit appreciable 
procoagulant activity.  Overall, these results demonstrate the viability of the claim 
that these bilayers can be used as tightly-controlled membrane surfaces upon 
which to control, assemble and study the components of the blood coagulation 
cascade at the nanoscale level. 
 
2.4 FIGURES 
 
 
 
 
Figure 2.1 PS composition of Nanodiscs.  PS content of Nanodiscs with 7.7 
nm-diameter bilayers.  Nanodiscs of varying PS compositions were prepared, to 
which trace amounts of 3H-PS were added during self-assembly.  Scintillation 
counting was used to determine PS recovery.  The line is a plot of y = x, showing 
that the %PS in Nanodiscs is essentially identical to that of the initial lipid mixture.  
Inorganic phosphate analyses following complete oxidation of the samples 
demonstrated that the mean molar ratio of phospholipid to MSP was 67(±1):1.  
Since each Nanodisc contains two MSP molecules, the mean phospholipid 
content was therefore 134 ± 2 phospholipid molecules per Nanodisc. 
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Figure 2.2 Intermediate scattering functions for 7.7 nm-diameter bilayer 
Nanodiscs of varying PS content.  Dynamic light scattering for solutions of 
Nanodiscs with three representative PS compositions are shown:  A, 0%; B, 
90%; or C, 100% PS, analyzed in the presence (solid symbols) or absence (open 
symbols) of 2.5 mM CaCl2.  The coincidence of the curves ± Ca2+ (when the 
Nanodiscs contained from 0 to 90% PS, as seen in panels A and B) indicates 
lack of detectable aggregation induced by Ca2+.  Dynamic light scattering 
analyses of Nanodiscs with contents between 0 and 90% PS likewise exhibited 
no evidence of aggregation (not shown).  Some evidence of aggregation was 
observed, however, when the Nanodiscs contained 100% PS, as evidenced by 
the shifted curve in the presence of Ca2+ (panel C). 
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Figure 2.3 Size exclusion chromatographs for 10.8 nm diameter bilayer 
Nanodiscs of varying PS content. Normalized size exclusion chromatographs 
for solutions of Nanodiscs of three representative PS compositions are shown: A, 
0%; B, 70%; or C, 90% PS, analyzed in the presence (solid lines) or absence 
(dotted lines) of 2.5 mM CaCl2. Coincidence of curves in A and B in the presence 
of absence of Ca2+ indicate lack of detectable aggregation. Size exclusion 
chromatography of Nanodiscs with contents between 0 and 70% PS, likewise, 
exhibited no evidence of aggregation (not shown). Some evidence of aggregation 
was observed, however, when Nanodiscs contained 90% PS, as evidenced by 
the shouldering at ~18 min in the presence of Ca2+.
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Figure 2.4 Representative gel filtration chromatographs of 7.7 nm-
diameter bilayer Nanodisc preparations.   Normalized size exclusion 
chromatographs for TF-free Nanodiscs (dotted lines) and enriched TF-Nanodiscs 
(solid lines). Comparison of curves indicates a faster elution time for TF-
Nanodiscs, corresponding to a slightly larger Stokes diameter than TF-free 
Nanodiscs.  These samples contained 75% PS (with the balance being PC) and 
were loaded sequentially on an equilibriated size-exclusion column monitored at 
A280. 
 
 
Figure 2.5 Number of tissue factor molecules per Nanodisc.  A standard 
curve was prepared by resolving samples, in duplicate, containing known 
quantities of purified TF and MSP (first eight lanes) on SDS-PAGE, staining the 
gel with Coomassie Blue and digitizing using a scanning densitometer (analyzed 
using Scion Image software, Scion Corporation, Frederick, MD).  Purified TF-
Nanodiscs were resolved on the same gel (rightmost two lanes) and quantified in 
parallel with the standards, yielding a determination of 0.51 TF/MSP molecule, or 
1.02 TF molecules/TF-Nanodisc.
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Figure 2.6 Clotting activity of TF-Nanodiscs containing varying PS 
content.  The ability of TF-Nanodiscs of varying PS content (from 20 to 100 
mol%) to shorten the clotting time of plasma was assayed via a standard 
prothrombin time test as a function of TF concentration.  Total phospholipid 
concentration was held constant at 50 µM. 
 
 
 
 
 
Figure 2.7 Clotting activity of three tissue factor preparations.  TF-induced 
clot times were measured for tissue factor relipidated into Nanodiscs (TF-
Nanodiscs), tissue factor relipidated into liposomes (TF-liposomes), and a 
mixture of soluble tissue factor (sTF) plus PCPS vesicles.  Tissue factor 
concentration was varied and total phospholipid concentration was held constant 
at 50 µM and at 20% PS for all preparations.  sTF concentrations below 1 ng/ml 
produced clot times of > 300 s.
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CHAPTER 3 
 
THE LOCAL PHOSPHOLIPID ENVIRONMENT MODULATES THE 
ACTIVATION OF BLOOD CLOTTING 
 
 
3.1 BACKGROUND 
 
In both normal hemostasis and many life-threatening thrombotic diseases, 
blood clotting is triggered when tissue factor (TF), an integral membrane protein, 
binds the plasma serine protease, factor VIIa (fVIIa) [1].  The resulting two-
subunit, membrane-bound enzyme, TF·VIIa, activates the plasma zymogens, 
factors IX (fIX) and X (fX), by limited proteolysis.  Erwin Chargaff (of nucleic acids 
fame) demonstrated in the 1940s that TF procoagulant activity requires it to be 
associated with phospholipids, and research over the ensuing decades 
demonstrated that TF is a membrane-spanning protein that must be incorporated 
into bilayers containing anionic phospholipids for optimal activity (reviewed by 
Bach [2]).  Despite this extensive history, we still have an indistinct picture of how 
anionic phospholipids contribute so profoundly to the enzymatic activity of 
membrane-bound protease complexes involved in blood clotting [3].   
Membranes composed of mixed phospholipids (and other lipids) can form 
membrane microdomains with locally different surface properties.  A noted 
example is the formation of cholesterol- and sphingolipid-rich lipid rafts and 
caveolae on cell surfaces [4,5].  Experiments using giant unilamellar vesicles 
have shown that even liposomes containing simple binary mixtures of neutral and 
anionic phospholipids spontaneously form anionic phospholipid-rich membrane 
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microdomains in the presence of plasma concentrations of Ca2+, which is even 
more pronounced in the presence of membrane-binding proteins [6,7].  Thus, 
anionic phospholipids were shown to coalesce, via lateral diffusion over relatively 
large distances, into subdomains several µm in size.  These and other studies 
have demonstrated that local membrane microenvironments can differ 
dramatically from the average composition of the membrane even in relatively 
“simple” model membranes. 
Most clotting proteins bind reversibly and in a Ca2+-dependent manner to 
bilayers containing anionic phospholipids—with phosphatidylserine (PS) being 
most active.  Local differences in membrane microdomain properties mean that 
specific proteins may tend to partition into or out of such microdomains, and so 
the lipid composition in the immediate vicinity of membrane-bound protease-
cofactor complexes may be expected to profoundly influence their enzymatic 
activities.  For example, TF-bearing microparticles have been reported to arise 
from lipid rafts [8], and depletion of cholesterol from cell membranes impairs 
functional TF expression in fibroblasts [9].  TF has also been reported to 
associate with caveolae on some cell surfaces [10-12].  The mechanisms by 
which specific plasma membrane domains may regulate the rate of clotting 
reactions are largely unknown, however.  Membrane-binding protein substrates 
such as fX are known to partition between the solution phase and the membrane 
surface, and most likely they also partition into specific membrane microdomains.  
We therefore hypothesize that blood clotting reactions such as the activation of 
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fX by the TF·VIIa complex occur preferentially, or at least with greatest efficiency, 
within membrane microdomains that have locally very high PS content. 
fX molecules bound to the membrane may translate on the membrane via 
lateral diffusion, effectively skating or hopping along the surface.  This leads to at 
least two different possible mechanisms by which protein substrates such as fX 
can encounter the TF·VIIa complex.  In one mechanism, solution-phase fX binds 
directly to the membrane-bound TF·VIIa complex, whereupon it is activated to 
fXa via limited proteolysis.  In another mechanism, membrane-bound fX 
molecules that are translating along the membrane surface (via lateral diffusion 
or hopping) encounter the TF·VIIa complex.  Several studies have addressed the 
relative importance of these two modes of substrate delivery to the TF·VIIa 
complex, typically by incorporating TF into liposomes of defined phospholipid 
composition, assembling the TF·VIIa complex, and then quantifying rates of fX 
activation.  These approaches have allowed somewhat indirect inferences to be 
made regarding the choice of solution-phase versus membrane-bound fX as the 
preferred substrate, in which the investigators systematically vary the liposome 
concentration and also use competing membrane-binding proteins.  Using such 
approaches, some investigators have concluded that the membrane-bound pool 
of fX is the preferred substrate [13], while others have concluded the opposite—
that solution-phase fX is the preferred substrate for the TF·VIIa complex [14,15]. 
In this study, we tested the concept that the local membrane 
nanoenvironment surrounding coagulation protease-cofactor complexes controls 
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both their assembly and catalytic efficiencies toward membrane-bound protein 
substrates.  We approached this by incorporating TF into nanoscale phospholipid 
bilayers that allow rigorous control of the local membrane microenvironment.  
This was accomplished using a unique system of stable nanoscale phospholipid 
bilayers, termed Nanodiscs [16], as a platform for studying membrane-protein 
interactions.  Water-soluble Nanodiscs are produced by a self-assembly process 
resulting in a nanoscale lipid bilayer (about 8 nm in diameter) encircled and 
stabilized by two copies of an amphipathic helical protein termed membrane 
scaffold protein (MSP).  This self-assembly is reproducible and efficient, yielding 
monodisperse preparations of supported lipid bilayers that are extremely stable 
and that exhibit lipid fluidity comparable to liposomes [17,18].  Moreover, 
heterologous membrane-spanning proteins can also be incorporated efficiently 
into these supported nanobilayers during self-assembly [19,20].  By embedding 
TF into nanoscale lipid bilayers, we can preclude long-distance (µm scale) 
recruitment of PS molecules into membrane domains with locally high or low PS 
content.  Instead, the composition of the membrane nanodomain immediately 
surrounding the TF·VIIa complex is under tight experimental control.  Using this 
system, we report that full TF·VIIa proteolytic activity required extremely high 
local concentrations of anionic phospholipids, and furthermore that a large pool of 
membrane-bound fX was not required to support efficient catalysis. 
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3.2 EXPERIMENTAL PROCEDURES 
 
3.2.1 Materials 
 
Phosphatidylcholine (PC; 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine) and PS (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine) were 
from Avanti Polar Lipids (Alabaster, AL), fVIIa was from American Diagnostica 
(Greenwich, CT) and fX was from Enzyme Research Laboratories (South Bend, 
IN).  Recombinant human TF [21] and MSP [16] were expressed in E. coli and 
purified as described. 
 
3.2.2 Measuring the Binding of fVIIa to TF-Nanodiscs and Rates of fX 
Activation 
 
Binding affinities of fVIIa for TF in liposomes or Nanodiscs were quantified 
using the TF-dependent increase in fVIIa enzymatic activity as described [22].  
Initial rates of fX activation by the TF·VIIa complex (assembled either on TF-
liposomes or TF-Nanodiscs) were quantified using a continuous fX activation 
assay as previously described [22].  Rates of fXa generation were measured over 
a 20 min period and in all cases were linear over the entire time course.  In all 
kinetic experiments, the final TF concentration was 5 pM in both the TF-Nanodisc 
and TF-liposome systems.  For TF-Nanodisc experiments, a molar ratio of 1 TF-
Nanodisc: 9 TF-free Nanodiscs was used, yielding final concentrations of 50 pM 
Nanodiscs and 6.7 nM phospholipid.  For TF-liposome experiments, the final 
phospholipid concentration was 65 nM.  Km and kcat values were calculated by 
fitting the Michaelis-Menten equation to the rate data using nonlinear regression. 
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3.2.3 Surface Plasmon Resonance Analyses 
 
Binding of fX to Nanodiscs containing varying mol% PS was quantified by 
surface plasmon resonance using a Biacore 3000 instrument.  NTA Biacore 
sensor chips were charged with Ni2+ according to the manufacturerʼs 
recommendations, after which Nanodiscs were immobilized on the NTA-Ni2+ chip 
surface via the oligohistidine tag located on MSP.  An empty NTA-Ni2+ channel 
was used to subtract changes in resonance units (RU) due to the refractive index 
of the protein solution and any non-specific binding.  Running buffer (10 mM 
HEPES-NaOH pH 7.4, 150mM NaCl, 2.5mM CaCl2) was flowed at 5µL/min.  
Nanodiscs were loaded onto each channel in calcium-free running buffer until a 
signal of 800 RU was achieved, after which a steady baseline was established in 
running buffer.  Increasing concentrations of fX were injected in running buffer 
and the maximal response above the baseline upon reaching steady state was 
recorded for each injected concentration.  The maximal RU values achieved at 
each fX concentration were then used to evaluate the affinity (Kd) of fX for the 
nanoscale bilayers.  This approach avoids potential limitations from analyzing 
association and dissociation rate data due to mass transport-limited rates of 
analyte association and analyte rebinding during the dissociation phase.  At the 
end of each run, NTA chips were regenerated using a buffer containing 0.3 M 
EDTA, which successfully removed the Nanodiscs and all bound proteins.  NTA 
sensor chips were reused for multiple binding experiments with no observed loss 
of function. 
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3.3 RESULTS AND DISCUSSION 
 
In this study we examined how changes in the local composition of the 
membrane immediately surrounding the TF·VIIa complex modulated its ability to 
proteolytically activate its membrane-binding substrate, fX.  We approached this 
by embedding TF into supported nanoscale lipid bilayers (Nanodiscs), in order to 
preclude long-distance recruitment of PS molecules into membrane subdomains 
with locally high or low PS contents.  As presented below, we then measured the 
ability of the TF·VIIa complex to assemble and function within these nanoscale 
bilayers as the local PS content was altered over a very broad range (0 to 90% 
PS).  In order to show the general trends observed with conventional liposome-
based approaches, we obtained data with the TF·VIIa complex assembled on TF-
liposomes of varying phospholipid composition (from 0 to 40% PS).  For the 
reasons outlined in the Introduction, however, it is not really possible to compare 
directly the results obtained using these two forms of TF, since we have no 
experimental control over the local PS content surrounding the TF·VIIa complex 
assembled on TF-liposomes.  Furthermore, because conventional liposomes 
containing extremely high PS contents undergo vesicle fusion and collapse when 
exposed to mM concentrations of Ca2+ [23], it  is likewise not possible to study 
the effects of high total PS content in conventional TF-liposomes. 
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3.3.1 Size Considerations 
 
In order to successfully investigate the activation of blood coagulation 
using the Nanodisc system, it was essential to demonstrate that the enclosed 
nanobilayer has sufficient room to assemble the TF·VIIa complex and also to 
productively bind at least one substrate (fX) molecule.  The cross-sectional area 
of the membrane-binding domain of fVIIa (the Gla domain) is ~3.9 nm2 [24], and 
the surface area of a phospholipid headgroup is ~0.7 nm2 [25], so the Gla domain 
covers roughly six phospholipid molecules.  The nanobilayers in these 
Nanodiscs, which contain 67±1 phospholipid molecules per leaflet (see below), 
should therefore have room to bind as many as ten Gla domains per leaflet.  But 
the cross-sectional area of the widest part of the TF·VIIa complex—near the 
globular fVIIa protease domain—is 16 to 18 nm2 [24], or enough to cover 23 to 26 
phospholipid molecules.  The relative sizes of these structures are displayed 
graphically in Fig. 3.1A, in which the crystal structure of the TF·VIIa complex is 
placed, to scale, on a schematic of the 8 nm supported bilayer contained within a 
Nanodisc.  Although the widest part of the TF·VIIa complex is around the globular 
protease domain of fVIIa, the two points of membrane contact in the TF·VIIa 
complex are considerably smaller.  Furthermore, since the supported bilayer in 
Nanodiscs has a boundary, portions of the TF·VIIa complex located near the 
protease domain could project beyond the edge of the bilayer.  This is 
demonstrated graphically in Figs. 3.1B and C, in which a “top” view of the crystal 
structure of the TF·VIIa complex is placed, to scale, on an 8 nm diameter circle 
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representing the size of the supported nanobilayers [26].  In this case, over 60% 
of the surface of the leaflet remains available for binding fX molecules.  The 
three-dimensional structure of zymogen fX is not known with certainty but fX is 
highly homologous to fVII (including its Gla domain) and likely has a similar 
cross-sectional area.  With 60% or more of the disc surface still available on 
discs containing the TF·VIIa complex, as many as six fX molecules could also 
possibly bind to the remaining leaflet.  However, factors such as the mobility of 
TF·VIIa in the lipid bilayer and the need for fX to bind in a specific orientation 
relative to TF·VIIa might reduce the available area somewhat.  Thus, the lipid 
bilayer in a Nanodisc is large enough to assemble the TF·VIIa complex and also 
bind at least one fX molecule, and perhaps as many as five or six. 
 
3.3.2 Binding of fX to Nanoscale Bilayers 
 
Incorporating PS into TF-liposomes of mixed phospholipid content 
enhances TF·VIIa proteolytic activity, with maximal rates of fX activation 
generally achieved at 10 to 40% PS [27,28].  This rate enhancement requires the 
presence of the Gla domain on fX, which mediates reversible binding of this 
protein to membranes containing PS.  Accordingly, we used surface plasmon 
resonance to examine the ability of nanoscale bilayers of varying PS content to 
bind fX.  Fig. 3.2A shows plots of the maximal RU values obtained at steady state 
for binding of fX to Nanodiscs of varying PS content, plotted as amount bound 
versus fX concentration.  Negligible quantities of fX bound to Nanodiscs 
containing only PC, but as the PS content of the nanobilayers increased, fX was 
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observed to bind to Nanodiscs in a saturable, concentration-dependent manner 
in which both the affinity and total amount of fX binding increased with increasing 
PS content.  The single-site ligand binding equation fit very well to the data at all 
PS contents (Fig. 3.2A), from which Kd values were obtained.  Binding affinities 
increased (i.e., Kd values decreased) as a function of increasing PS content (Fig. 
3.2B), with an almost linear dependence of binding free energy on PS content 
(Fig. 3.2C).  The Kd values obtained with Nanodiscs containing 54 or 67 PS 
molecules per leaflet (i.e., 80 or 100% PS) were in the range of literature values 
for fX binding to liposomes containing 20 to 30% PS [29,30].  Interestingly, the 
amount of fX bound to Nanodiscs at saturation increased steadily as the PS 
content increased (Fig. 3.2D), and indeed previous studies using liposomes have 
estimated that one fX molecule engages approximately five PS molecules [29].  
Thus, Nanodiscs with very high PS content will contain more fX binding sites, and 
as the PS molecules are more closely packed within the bilayer they will bind fX 
with higher affinity. 
As demonstrated above, there is theoretically sufficient room on 
Nanodiscs to bind up to ten fX molecules per leaflet.  Stoichiometric calculations 
of fX molecules bound per Nanodisc can be estimated from SPR signals if the 
bound molecules have equivalent impact on the refractive index.  Previous 
studies have shown that phospholipid bilayers in the fluid phase have similar 
refractive indices compared with protein solutions [31,32].  Therefore, at 
saturation the molar ratio of fX to Nanodiscs equals 
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(RUfX/RUdiscs)*(MWdiscs/MWfX).  In our experiments, 800 RU of Nanodiscs were 
loaded onto the sensor chips.  The maximal amount of fX bound at steady state 
increased linearly as a function of the PS content of the Nanodiscs, with 5100 RU 
of fX bound at saturation to discs containing 100% PS.  Using masses of 154 
kDa for Nanodiscs containing 100% PS (i.e., 134 PS molecules at 784 Da each 
and 2 MSP molecules at 24.7 kDa each) and 59 kDa for fX, we calculated 16.6 fX 
molecules bound per Nanodisc (i.e., 8.4 fX bound per leaflet) at saturation (Fig. 
3.2D).  This agrees well with the maximal estimate of about ten fX molecules per 
leaflet based solely on the surface area of a Gla domain.  Using 0.7 
nm2/phospholipid, this corresponds to a surface coverage of 29 pmol fX/cm2, 
which is significantly higher than reported in the literature in experiments using fX 
binding to liposomes [30,33].  We attribute this apparently higher coverage to the 
fact that Nanodiscs have boundaries beyond which the globular portions of these 
proteins can project (as demonstrated graphically by the TF·VIIa complex in Fig. 
3.1), and also to the very high local PS content of these Nanodiscs (leading to a 
higher density of potential fX binding sites). 
 
3.3.3 Assembling the TF·VIIa Complex on Nanoscale Bilayers 
 
Most of the binding energy of the TF·VIIa complex comes from protein-
protein interactions, but some additional binding energy is provided by protein-
membrane interactions between the fVIIa Gla domain and anionic phospholipids, 
thereby reducing the Kd for assembling TF·VIIa from ~2 nM to less than 50 pM 
[27].  In the present study we found that binding of fVIIa to TF in liposomes or 
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Nanodiscs was enhanced as the PS content of the bilayer increased, achieving 
Kd values below 30 pM for both presentations of TF (Fig. 3.3).  Interestingly, the 
tightest binding of fVIIa to TF-Nanodiscs was observed at the highest PS 
contents (70 and 90% PS).  This is consistent with the notion that locally very 
high PS content favors the binding of Gla domain-containing proteins such as 
fVIIa to membrane surfaces.  This also suggests that the TF·VIIa complex will 
have highest affinity for, and therefore likely to partition into, membrane 
subdomains with locally very high PS content.  Our findings also demonstrate 
that it is possible to assemble fully functional TF·VIIa complexes on 8 nm 
diameter bilayers. 
 
3.3.4 Local PS Composition Influences Rates of fX Activation by TF·VIIa 
 
As expected from many previous studies, increasing the PS content of TF-
liposomes decreased the apparent Km for fX activation by TF·VIIa (Fig. 3.4A).  
With TF-Nanodiscs, the Km for fX decreased monotonically as the PS content 
increased (Fig. 3.4B), paralleling the PS dependence of fX binding to Nanodiscs 
(cf. Fig. 3.2B).  Interestingly, the lowest Km values with TF-Nanodiscs were 
obtained at the highest PS content (containing 60 PS molecules per leaflet, or 
90% PS).  It should also be noted that these kinetic experiments employ 50 pM 
Nanodiscs, each of which can bind a maximum of about 16.6 fX molecules.  
Thus, the maximal concentration of membrane-bound fX is about 0.8 nM, which 
is far below the fX concentrations used in our kinetic analyses.  For this reason, 
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the concentration of total fX and free fX are essentially identical in our kinetic 
studies using TF-Nanodiscs. 
We obtained similar apparent kcat values when TF·VIIa complex was 
assembled on TF-Nanodiscs and TF-liposomes, ranging from about 1 to 4 s-1 
(Fig. 3.4C), although the trends in kcat values differed somewhat between TF-
liposomes and TF-Nanodiscs as the PS content increased.  With TF-liposomes 
the second-order rate constant for fX activation (kcat/Km) increased continuously 
with increasing %PS from 10 to 40% PS, and with TF-Nanodiscs it increased 
from 10 to 70% PS (equivalent to 47 PS molecules per leaflet).  Taken together, 
these results indicate that the TF·VIIa complex is most active when the local PS 
content is very high (70% PS and above). 
 
3.3.5 Mechanisms of Substrate Presentation to TF·VIIa 
 
Our findings demonstrate that the TF·VIIa enzyme complex can efficiently 
activate its natural protein substrate, fX, even when this membrane-bound 
enzyme complex is constrained within a nanoscale lipid bilayer consisting of only 
~67 phospholipid molecules per leaflet.  From indirect analyses using TF-
liposomes, some have suggested that solution-phase fX may be the preferred 
substrate for TF·VIIa [14,15], while others have argued that the pool of 
membrane-bound fX represents the preferred substrate [13].  The TF·VIIa 
complex assembled on Nanodiscs, unlike the situation on liposomes, does not 
have access to a large pool of membrane-bound fX molecules that can be used 
to deliver substrate to the enzyme over long distances by lateral diffusion or 
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hopping.  Instead, the tiny membrane surface corralled inside the Nanodisc can 
bind at most five or six fX molecules when the TF·VIIa complex is present, as 
discussed above.  Given the rates of fX activation observed in Fig. 3.4, it should 
take only two or three seconds to convert all these membrane-bound fX 
molecules to fXa.  Instead, we observed linear rates of fX activation that were 
sustained over 20 min.  At a kcat of 2 s-1, each TF·VIIa complex activates 2400 fX 
molecules during this 20 min time course.  Therefore, the TF·VIIa complex must 
rely on continuous binding of substrate (fX) to, and dissociation of product (fXa) 
from the nanobilayer, in order to allow such sustained rates of fX activation.  On 
the other hand, the much larger membrane surface on liposomes can bind many 
hundreds of fX molecules, theoretically allowing the TF·VIIa complex to choose 
between the membrane-bound pool of fX molecules laterally diffusing on the 
membrane surface or solution-phase fX molecules that bind directly to TF·VIIa or 
to the membrane immediately adjacent to complex.  The fact that kcat values 
obtained with TF-Nanodiscs rival those of TF-liposomes indicates that the 
TF·VIIa complex is not absolutely dependent on a large, preexisting pool of 
membrane-bound fX to serve as substrate. 
With TF-liposomes, kcat values increased as the %PS increased (up to 
40% PS), but TF-Nanodiscs did not exhibit this behavior.  Hathcock et al., [30,34] 
proposed that removal of fXa from the vicinity of the TF·VIIa complex by lateral 
diffusion on the membrane surface is likely the rate-limiting process controlling 
the apparent kcat.  However, this mechanism of product removal from the TF·VIIa 
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complex is likely to be less effective when the TF·VIIa complex is constrained 
within nanoscale bilayers. 
Coagulation serine proteases and the corresponding protease-cofactor 
complexes (including TF·VIIa) have evolved exosites to increase substrate 
specificity [35].  Exosites are distinct binding sites lying outside the proteaseʼs 
active site that can enhance binding of protein substrates, inhibitors and other 
regulatory molecules.  In fact, exosites may be located on the protease, the 
protein cofactor, or both.  We propose that a small patch of anionic phospholipids 
located on the membrane surface in the immediate vicinity (i.e., within a few nm) 
of TF serves as an additional exosite to enhance the binding affinity of protein 
substrates like fIX and fX to the TF·VIIa complex.  This contributes in an 
important way to the substrate specificity of this extremely selective activator of 
the blood clotting cascade. 
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3.4 FIGURES 
 
 
 
 
Figure 3.1 Schematic of the TF·VIIa complex on an 8 nm supported 
nanoscale bilayer.  A, The TF·VIIa crystal structure (PDB file 1DAN [24]) is 
placed, to scale, on a schematic of the 8 nm diameter bilayer in a Nanodisc [16].  
TF is colored brown, fVIIa is blue (with active site inhibitor in white), phospholipid 
headgroups are depicted as red spheres, and amphipathic helices of the 
encircling MSP are depicted as purple cylinders.  B, “Top” view of the TF·VIIa 
complex placed near the edge of an 8 nm diameter bilayer (represented by a 
green circle), with only the Gla domain of fVIIa and the “bottom” portion of TF 
rendered as space filling atoms; the rest of the TF·VIIa structure (except the 
active site inhibitor) is rendered as wires.  C, Same view as in panel B, but with 
the entire TF·VIIa complex rendered as space-filling atoms. 
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Figure 3.2 Binding of fX to Nanodiscs of varying PS content, measured 
by surface plasmon resonance.  A, Steady-state binding of fX to Nanodiscs 
with the indicated number of PS molecules per leaflet (with the corresponding 
mol% PS in parentheses), as a function of fX concentration.  Lines are the single-
site ligand binding equation fitted to the data.  B, Kd values derived from binding 
isotherms as depicted in panel A.  C, Free energies calculated from Kd values in 
panel B.  D, Rmax (maximal RU values) at saturating fX concentrations.  Data 
represent mean ± S.E.M. (n = 3).  The lower x axes in panels B-D represent the 
calculated number of PS molecules per leaflet, while the upper x axes are the 
mol% PS.  The right y axis in panel D represents the number of fX molecules 
bound per leaflet, calculated as described in the text. 
 
 
62 
 
 
 
Figure 3.3 Locally high PS content supports high affinity binding of fVIIa 
to TF.  Kd values were measured for the association of fVIIa with TF incorporated 
into liposomes (A) and Nanodiscs (B) as a function of PS content.  The lower x 
axis in panel B represents the calculated number of PS molecules per leaflet, 
with mol% PS indicated on the upper x axis. 
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Figure 3.4 Locally high PS content promotes fX activation by TF·VIIa.  
The following kinetic constants were measured for fX activation by TF·VIIa:  Km 
using TF-liposomes (A) or TF-Nanodiscs (B);  kcat using TF-liposomes (C) or TF-
Nanodiscs (D); and kcat/Km using TF-liposomes (E) or TF-Nanodiscs (F).  Data 
represent mean ± S.E.M. (n = 4).  The lower x axes in panels B, D and F 
represent the calculated number of PS molecules per leaflet, with mol% PS 
indicated on the upper x axes.  Under our experimental conditions, rates of fX 
activation were essentially undetectable using TF-liposomes or TF-Nanodiscs 
containing 100% PC, precluding their inclusion in this figure.
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CHAPTER 4 
 
INFLUENCE OF THE LOCAL PHOSPHOLIPID NANOENVIRONMENT ON 
PROTHROMBINASE FUNCTION 
 
 
4.1 BACKGROUND 
 
Prothrombin is converted to thrombin by the serine protease, factor Xa 
(fXa), in complex with its protein cofactor, factor Va (fVa) [1,2]. This complex of 
fVa and fXa – often called prothrombinase – assembles in a Ca2+-dependent 
manner on suitable membrane surfaces [3,4]. In addition to providing a platform 
for prothrombinase assembly, biological membranes also modulate the catalytic 
activity of prothrombinase and other serine protease-cofactor complexes in blood 
clotting [5]. Studies using liposomes and other model membranes have shown 
that anionic phospholipids are required for optimal prothrombinase activity, with 
phosphatidylserine (PS) being the most active [5,6]. Unfortunately, the 
mechanisms by which PS enhances the enzymatic activity of prothrombinase – 
or indeed any other protease-cofactor complex in blood clotting – are not fully 
understood. 
We hypothesize that prothrombinase and other blood clotting protease-
cofactor complexes partition into membrane microdomains of locally very high 
PS content. Studies of giant unilamellar vesicles composed of mixtures of anionic 
and neutral phospholipids have shown that plasma concentrations of Ca2+ can 
induce anionic phospholipids to move over relatively long distances to cluster into 
anionic phospholipid-rich membrane domains. Clustering of anionic 
phospholipids was even more dramatic when vesicles were treated with 
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combinations of Ca2+ and proteins known to bind to anionic phospholipids, such 
that the membrane-binding proteins co-clustered with anionic phospholipids [7,8]. 
It therefore seems likely that blood clotting reactions occur preferentially on 
membrane surfaces containing locally high PS content, which may result from 
both calcium ions and the PS-binding properties of the proteins themselves. 
Unfortunately, when using even simple model membranes, it is very difficult to 
know the phospholipid composition immediately surrounding the membrane-
bound prothrombinase complex and its membrane-bound substrate, prothrombin. 
In the presence of plasma concentrations of Ca2+, liposomes composed of 20% 
PS and 80% phosphatidylcholine (PC) are likely to segregate into a patchwork of 
microenvironments in which the local PS content at any given point may be 
considerably higher or lower than the average of 20%. Thus, local variations in 
the membrane nanoenvironment immediately surrounding prothrombinase may 
dramatically alter its catalytic efficiency. When using liposomes or other model 
membranes, this parameter is typically not under experimental control. 
In the present study, we used supported nanometer-scale phospholipid 
bilayers (Nanodiscs) of defined size and phospholipid composition as the 
experimental membrane surface upon which to assemble and study the 
components of the prothrombinase complex. Nanodiscs are water-soluble 
bilayers encircled and stabilized by an amphipathic helical protein termed 
membrane scaffold protein (MSP). The nanobilayers within Nanodiscs are 
monodisperse and exhibit lipid fluidity comparable to liposomes [9,10]. Nanodiscs 
self-assemble from mixtures of phospholipid and MSP, yielding stabilized 
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nanoscale bilayers whose lipid composition is under strict experimental control. 
Newer-generation Nanodiscs have been developed using MSPs that have been 
systematically elongated or truncated to yield stabilized, monodisperse 
phospholipid bilayers ranging from about 8 to 15 nm in diameter [11]. By 
assembling the constituent proteins of the prothrombinase complex on these 
nanobilayers, we can circumvent the long-range recruitment of anionic 
phospholipids that occurs in larger phospholipid systems such as liposomes. This 
affords us complete control over the composition of the membrane 
nanoenvironment immediately surrounding the prothrombinase complex. Our 
results now demonstrate how locally high PS concentrations regulate 
prothrombinase assembly and function. 
 
4.2 EXPERIMENTAL PROCEDURES 
 
4.2.1 Materials 
 
PC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), PS (1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphoserine) and the lipid extruder were from Avanti Polar 
Lipids (Alabaster, AL). Benzamidine was from Fisher Scientific (Pittsburg, PA). 
Human prothrombin and fXa were from Enzyme Research Laboratories (South 
Bend, IN). DAPA (dansylarginine N-(3-ethyl-1,5-pentanediyl)amide) and fVa were 
from Haematological Technologies, Inc. (Essex Junction, VT). Nanodisc 
Membrane Scaffold Proteins, MSP1D1 and MSP1E3D1 were expressed in E. 
coli and purified as previously described [12]. 
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4.2.2 Surface Plasmon Resonance Analyses 
 
Binding of prothrombin, fXa and fVa to Nanodiscs of varying mol% PS was 
quantified by surface plasmon resonance using a Biacore 3000 instrument and 
NTA Sensor Chips (Piscataway, NJ) as described [13], with the following 
modifications: After the NTA chips were charged with Ni2+, Nanodiscs containing 
a 6xHis tag in the MSP were loaded onto each channel in calcium-free running 
buffer until a signal of 600 to 800 RU was achieved. A steady baseline was then 
established in running buffer (10 mM HEPES-NaOH pH 7.4, 150 mM NaCl, 2.5 
mM CaCl2), after which increasing concentrations of the desired protein were 
injected. Upon reaching steady-state binding, the maximal RU response above 
baseline was recorded. The single-site ligand binding equation was fitted to these 
steady-state RU values to calculate the Kd of protein binding to the nanoscale 
bilayers. Membrane binding of fXa and prothrombin was quantified using 
Nanodiscs with 7.7 nm-diameter bilayers as described for factor X [13], except 
that 5 mM benzamidine was included in the buffers when fXa was used. 
Membrane binding of fVa was quantified using Nanodiscs with 10.8 nm-diameter 
bilayers. 
The numbers of protein molecules (prothrombin, fXa, or fVa) bound at 
saturation per Nanodisc leaflet were calculated by assuming that protein and 
phospholipid bilayers have equivalent effect on refractive index, as has been 
previously demonstrated [13-15]. The molar ratio of bound protein molecules to 
Nanodiscs at saturation equals (RUprotein/RUNanodisc)*(MWNanodiscs/MWprotein), with 
RUNanodiscs corresponding to the amount of Nanodiscs loaded onto the sensorchip, 
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and RUprotein corresponding to the amount bound analyte at saturation (the latter 
calculated from the fitted single-site ligand binding equation). MWprotein 
corresponds to the molecular weights of the proteins of interest: 173 kDa for fVa, 
46 kDa for fXa, and 72 kDa for prothrombin. MWNanodiscs is the sum of the 
constituent masses. The molecular weight of MSP1D1 is 24.7 kD and of 
MSP1E3D1 is 32.6 kDa, with two copies of each MSP per Nanodisc. The 
molecular weights of PC and PS are 760 and 784 Da, and there are 134 or 240 
phospholipid molecules per 7.7 or 10.8 nm-diameter bilayer, respectively. 
 
4.2.3 Rates of Prothrombin Activation 
 
Initial rates of prothrombin activation by the prothrombinase complex, 
assembled either on liposomes or Nanodiscs (10.8 nm-diameter bilayers) of 
varying mol %PS, were quantified using a continuous DAPA-based prothrombin 
activation assay [16,17]. Briefly, prothrombin activation reactions were conducted 
in HEPES-buffered saline (20 mM HEPES-NaOH pH 7.4, 150 mM NaCl, 2.5 mM 
CaCl2, 0.1% polyethylene glycol 8000) containing 4.5 nM fVa, 10 μM DAPA, 
varying prothrombin concentrations and either liposomes (5 μM phospholipid)  or 
10.8 nm-diameter Nanodiscs (2.5 μM phospholipid).  Thrombin generation was 
initiated by adding 60 pM fXa, and DAPA fluorescence was monitored over time 
(excitation at 280 nm, emission at 545 nm, and cutoff at 515 nm) using a 
Spectramax Gemini XS microplate fluorometer (Molecular Devices; Sunnyvale, 
CA). Km and kcat values were calculated by fitting the Michaelis-Menten equation 
to the rate data using nonlinear regression. 
 
 
73 
Prothrombin activation by prothrombinase occurs via cleavage of two 
peptide bonds with two possible intermediates: meizothrombin, or prethrombin 2 
[17]. To determine the intermediates of prothrombin cleavage, reaction mixtures 
containing 4.5 nM fVa, 60 pM fXa, 1 μM prothrombin and 10 μM DAPA were 
activated on phospholipids (either 5 μM liposomes or 2.5 μM Nanodiscs with 10.8 
nm-diameter bilayers) in HEPES-buffered saline. Samples were quenched at 
fixed time points in 50 mM EDTA, heated to 90°C for 5 min, and resolved on 
SDS-PAGE. Bands were detected by staining with Coomassie. 
 
4.3 RESULTS 
 
In this study we investigated how the membrane composition immediately 
surrounding prothrombinase modulates its assembly and enzymatic activity. To 
accomplish this we assembled the components of the prothrombinase complex 
on nanoscale phospholipid bilayers (Nanodiscs) of controlled phospholipid 
composition. Unlike liposomes and most other model membrane systems, the 
phospholipid bilayers in Nanodiscs cannot undergo long-range, Ca2+-induced 
reorganization of PS molecules into regions of locally high PS content, which 
allows us to define the membrane composition immediately under and 
surrounding prothrombinase. In our recent study of assembling the tissue factor-
factor VIIa complex on nanoscale bilayers, we found that 7.7 nm-diameter 
bilayers were large enough to accommodate fully functional tissue factor-factor 
VIIa complexes, allowing us to measure high rates of factor X activation [13]. The 
prothrombinase complex is larger than the tissue factor-factor VIIa complex, 
however, chiefly because fVa is about four times the size of tissue factor. We 
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therefore found that assembling the complete prothrombinase complex required 
the use of Nanodiscs containing 10.8 nm-diameter bilayers. On the other hand, 
we could readily quantify binding of fXa or prothrombin to nanobilayers to 
Nanodiscs containing 7.7 nm-diameter bilayers. 
 
4.3.1 Size Considerations 
 
In order to employ Nanodiscs to study the assembly and function of the 
prothrombinase complex, it was necessary to determine that the supported 
nanoscale bilayers have sufficient surface area to accommodate both fVa and 
fXa, and also to bind at least one substrate molecule (prothrombin). It should be 
pointed out that the membrane binding domains of these proteins have relatively 
small cross-sectional areas, while the larger, globular portions of fVa, fXa and 
prothrombin are free to project beyond the boundaries of the supported bilayers. 
Using individual crystal structures of the Gla domain of bovine fXa [18] and both 
C domains of bovine fVai [19], we created a schematic of the membrane contact 
domains of the constituent partner proteins of prothrombinase on a 7.7 and 10.8 
nm-diameter Nanodisc.  As displayed in Fig. 4.1A, the smaller 7.7 nm-diameter 
bilayer seems unlikely to support the entire complex.  However, the 10.8 nm-
diameter bilayer visually demonstrates that there should be sufficient room to 
accommodate prothrombinase and to bind multiple substrate molecules as well 
(Fig. 4.1B). 
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4.3.2 Binding of Prothrombin to PS-Containing Bilayers 
 
An essential function of PS is to promote binding of substrate 
(prothrombin) to the membrane surface in the vicinity of the prothrombinase 
complex. Accordingly, we used surface plasmon resonance to quantify the 
binding of prothrombin to immobilized nanoscale bilayers as a function of PS 
content. Previously, we used immobilized Nanodiscs containing 7.7 nm-diameter 
bilayers to quantify PS-dependent fX binding [13], so we also chose to use 
Nanodiscs of this size for studying the effects of PS content on membrane 
binding of prothrombin. Fig. 4.2A shows representative plots of steady-state RU 
values for binding of prothrombin to Nanodiscs of varying PS content. No 
appreciable prothrombin binding to Nanodiscs containing 100% PC was 
detected, but as the PS content increased, prothrombin bound to the nanoscale 
bilayers in a saturable, concentration-dependent manner. The single-site ligand 
binding equation fit well to the data in Fig. 4.2A, yielding Kd values that 
decreased monotonically as the PS content increased (Fig. 4.2B). This 
corresponded to a monotonic increase in binding energy with increasing PS 
content (Fig. 4.2C). The Kd values we obtained from Nanodiscs containing 60 to 
100% PS are within the range of literature values for prothrombin binding to 
liposomes composed of 20 to 30% PS [5]. 
We used the binding data from Fig. 4.2A to calculate the number of 
prothrombin molecules bound per leaflet, plotted in Fig. 4.2D as a function of PS 
content. At saturation, a maximum of about 8 prothrombin molecules can bind 
per 7.7 nm-diameter leaflet composed of 100% PS, which corresponds to about 
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one prothrombin binding site per 8.3 PS molecules. This is nearly identical to the 
maximal number of fX molecules bound per 7.7 nm-diameter bilayer composed 
of 100% PS [13]. 
 
4.3.3 Binding of fXa to PS-Containing Bilayers 
 
We next investigated the effect of local PS content on the membrane 
binding affinity of the components of the prothrombinase complex, starting with 
fXa. Using the same surface plasmon resonance approach that we used to 
quantifying prothrombin binding, we found that no appreciable fXa bound to 
nanoscale bilayers containing 100% PC. As the PS content increased, however, 
fXa bound to the nanobilayers in a saturable, concentration-dependent manner 
(Fig. 4.3A). The single-site ligand binding equation fit well to the data (Fig. 4.3A), 
yielding Kd values that decreased as the PS content increased from 20 to 60%, 
but which were relatively constant from 60 to 100% PS (Fig. 4.3B). The 
relationship between fXa binding and PS content is seen more clearly when 
binding energies are plotted as a function of PS content (Fig. 4.3C). For 
comparison purposes we have also plotted, in Figs. 4.3B and 4.3C, data for 
binding of zymogen fX to 7.7 nm-diameter nanobilayers collected under identical 
conditions [13]. The most striking difference between fX and fXa binding is that 
fXa exhibited higher binding affinity for nanobilayers from 20 to 60% PS, while 
the binding affinities of fX and fXa were essentially the same at high PS content 
(80 and 100% PS). 
The calculated maximal number of fXa molecules bound per nanobilayer 
were plotted in Fig. 4.3D as a function of PS content. Interestingly, at saturation 
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the nanobilayers bound more than twice as many fXa molecules per leaflet 
compared with fX, at all PS contents tested (Fig. 4.3D). Thus, a maximum of 
approximately 20 fXa molecules were found to bind to a 7.7 nm-diameter leaflet 
composed of 100% PS. This compares to only about 8 fX molecules per leaflet 
on the same type of surface, a difference in binding capacity of about 2.5-fold. 
The calculated number of PS molecules per protein at saturation is 3.4 PS 
molecules per fXa and 8.4 PS molecules per fX. 
 
4.3.4 Binding of fVa to PS-Containing Bilayers 
 
The other half of the prothrombinase complex is fVa, so we examined the 
PS-dependence of fVa binding to nanobilayers. In initial surface plasmon 
resonance experiments, we observed only weak binding of fVa to Nanodiscs 
containing 7.7 nm-diameter bilayers, but much stronger binding to Nanodiscs 
containing 10.8 nm-diameter bilayers (not shown). We therefore quantified fVa 
binding to the larger Nanodiscs as a function of PS content. We found no 
appreciable fVa binding to bilayers containing 100% PC, and very limited fVa 
binding at 10% PS (Fig. 4.4A). From 20 to 90% PS, however, fVa bound in a 
saturable, concentration-dependent manner, and the single-site ligand binding 
equation fit well to the data. The Kd values for fVa binding to PS-containing 
nanobilayers varied by only a small amount from 10 to 90% PS (Fig. 4.4B), 
reflected in relatively small changes in binding energy (Fig. 4.4C). At saturation, 
we found that a maximum of about 2 to 2.5 fVa molecules were bound per 10.8 
nm-diameter leaflet composed of 20-90% PS (Fig. 4.4D).  This corresponds to 
about one fVa binding site per 10 PS molecules when the nanobilayer contained 
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20% PS.  Bilayers with 10% PS bound very little fVa, suggesting that such 
bilayers lacked the minimum number of PS molecules to productively bind fVa. 
 
4.3.5 Prothrombin Activation on Nanoscale Bilayers 
 
The influence of local PS content on prothrombinase activity was 
investigated by assembling the prothrombinase complex on 10.8 nm-diameter 
bilayers of varying PS composition. A stoichiometric excess of Nanodiscs to fVa 
molecules was used to minimize the occurrence of more than one fVa molecule 
bound per Nanodisc leaflet. For comparison, the prothrombinase complex was 
also assembled on liposomes of varying PS content. On liposomes, the Km for 
prothrombin activation by prothrombinase dropped about two-fold between 8 and 
10% PS, and then decreased much more modestly as the PS content was further 
increased to 40% PS (Fig. 4.5A). On Nanodiscs, the Km was equally high at 10 
and 20% PS, but decreased almost linearly as the PS content increased to 70% 
(Fig. 4.5B).  The lowest Km on Nanodiscs was achieved at 70% PS, and was 
essentially equivalent to the Km obtained using liposomes containing 20 to 40% 
PS. 
The kcat values for prothrombin activation by prothrombinase on liposomes 
varied relatively little when liposomes contained 8 to 40% PS, but showed a 
maximum at 20% PS (Fig. 4.5C). On Nanodiscs, kcat was somewhat lower than 
on liposomes, and also varied somewhat more than on liposomes (Fig. 4.5D).  
Thus, on Nanodiscs kcat was maximal at 20% PS and then decreased almost 
linearly as the PS content increased from 30 to 70%. 
 
 
79 
On liposomes, kcat/Km increased from 8 to 30%, and then decreased 
slightly at 40% PS (Fig. 4.5D).  In contrast, on Nanodiscs kcat/Km increased 
almost linearly as the PS content increased from 10 to 70% PS (Fig. 4.5E). 
 
4.4 DISCUSSION 
 
4.4.1 The Local PS Environment Influences the Binding of Prothrombin, 
fXa, and fVa to Membranes 
 
We have found that prothrombin, fXa and fVa are dependent on high local 
concentrations of PS for high affinity membrane binding. By calculating the 
stoichiometric ratio of the number of protein molecules bound per leaflet of the 
Nanodisc from surface plasmon resonance data, we observed that as the PS 
content was raised, more proteins bind the membrane in a saturable, 
concentration-dependent manner. We have found that the maximal amount of 
prothrombin bound at steady-state increased linearly as a function of PS content 
in 7.7 nm diameter bilayer Nanodiscs. At saturation, 8 prothrombin molecules 
bound a 67 phospholipid leaflet composed of 100% PS (i.e., 16 prothrombin 
molecules per 7.7 nm diameter Nanodisc containing a total of 134 
phospholipids). This is consistent with our recent manuscript in which we 
demonstrated how 8 fX molecules bound a 67 phospholipid leaflet composed of 
100% PS [13]. It is of note that the two serine protease zymogens we have so far 
evaluated, fX and prothrombin, have footprints that cover the same amount of 
phospholipid headgroups. 
Our surface plasmon resonance studies with fXa showed that, at 
saturation, a total of ~20 fXa molecules were found on a 7.7nm diameter bilayer 
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Nanodisc leaflet; approximately twice the amount found for its zymogen form, fX. 
This suggests that, in the presence of Ca2+ and on a membrane bilayer 
composed of 100%PS, fXa can occupy twice the phospholipid surface area of fX. 
The two cleavage events that activate fX into fXa release an activation peptide 
fragment. The release of this peptide renders fXa 20% smaller than fX by 
molecular weight. Moreover, since the cleavage events are distal to the GLA 
domain, no considerable conformational changes in the GLA domain are 
predicted to occur. As discussed above, we have estimated that a 7.7 nm 
diameter membrane composed of only 67 phospholipids can bind, at a 
theoretical maximum, 10 to maybe 13 GLA domains. This prediction does not 
however take into account the entire protein, but only its membrane binding 
portion. Our results, therefore, exceed our maximal estimate for the GLA domain 
alone by a factor of ~2. Taken together, it is unlikely that the neither cleavage 
events alone, nor does a conformation change in the GLA domain account for 
the increase in the density of fXa compared to fX on the membrane surface. The 
two-fold increase in the lipid density of fXa, however, is highly suggestive that 
membrane-bound fXa is very efficiently packed and/or is dimerizing on the 
phospholipid surface. Interestingly, a recent study by Hathcock, et al. [20], also 
supports this hypothesis. Briefly, the authors also showed that the maximum lipid 
binding capacity of fXa exceeded that of fX by a factor of two. It was proposed 
that if fXa is indeed a monomer, it packs onto a membrane bilayer with extreme 
efficiency; nearly comparable to highly organized, hexagonally packed cylinders 
[20]. The authors suggest that although it is not impossible to pack proteins in 
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this manner, an alternative hypothesis is that the fXa molecule dimerizes on the 
membrane surface. In their model, the first fXa molecule binds phospholipids, 
while the second binds the first fXa molecule; effectively reducing the apparent 
number of phospholipids that fXa binds to in half. The fXa dimer model has also 
been previously proposed [21,22] and it has been speculated that dimerization of 
fXa serves to increase its phospholipid density. In turn, the high density of fXa 
may serve to out-compete fX and other substrates from the membrane surface. 
Perhaps coincidentally, our binding data also shows that compared to fX, fXa has 
a higher affinity for membranes containing low amounts of PS and equivalent 
affinity when the membrane has high PS content; hinting at the existence of a 
form of competitive mechanism between the fX and fXa on the membrane 
surface. 
The fVa molecule binds membranes via electrostatic and hydrophobic 
interactions [23-25] through an incompletely understood mechanism. Although 
fVa will bind membranes composed of pure PC, the reported Kd for this 
interaction is very weak (3 μM), and at least 2 orders of magnitude beyond the 
reported plasma concentration of fVa [26,27]. In order for fVa to bind membranes 
with high affinity and physiological relevance, PS molecules are required. 
Reportedly, as little as 10 PS molecules are needed for one fVa molecule to bind 
membranes [28]. Indeed, with our experimental conditions, we were able to 
detect binding with as little as ~12 PS molecules (the lowest PS content we 
evaluated) and we estimate that one fVa molecule will bind anywhere between 
12 to 24 PS molecules (Fig. 4.4D). As such, to achieve binding at physiological 
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levels, a minimum amount of PS molecules are simply required. Once binding 
has occurred, there is however, very little change in Kd as PS content is raised. 
We speculate that the qualitative changes in Kd values are largely due the 
inefficiency of fVa access to PS binding sites on a constrained nanobilayer. To 
elaborate, as the PS content of the Nanodiscs is increased, more fVa binding 
sites become available. However, because the size of the bilayer remains the 
same, fVa molecules must then compete for space in order to saturate the 
remaining binding sites. Indeed, as observed in Fig. 4.4D, a 10.8 nm diameter 
bilayer composed of 90% PS becomes saturated when only about 3 fVa 
molecules bind. This competition of PS binding sites within a limited surface area 
may account for the slight increase in the Kd for the interaction of fVa to 
membranes. 
On a resting cell or platelet surface, PS and other aminophospholipids are 
sequestered within the inner cell membrane and away from the circulation, while 
choline phospholipids such as PC are sequestered on the outer leaflet [3,29]. 
Upon cell damage or induction of other stressors, PS molecules are scrambled 
onto the outer leaflet. This manuscript and others have established that the 
binding of many plasma-derived blood coagulation proteins are PS dependent. 
Our results show no detectable binding of fVa to membranes in the absence of 
PS molecules. However, after a minimal number of PS molecules are reached, 
fVa begins to bind PS-containing membranes at high affinity, and below the total 
physiological concentration of its unactivated form, fV. A relatively small amount 
of PS (12-24 molecules) on the membrane surface is sufficient to induce high 
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affinity binding of fVa. This supports the oft-proposed idea that once bound to a 
membrane, fVa is responsible for priming the assembly of the prothrombinase 
complex [5]. We also show that the high affinity binding of fXa and prothrombin to 
membranes occur at a very high PS content. Likewise, the optimal Kd values of 
these vitamin K-dependent proteins are near or below the reported plasma 
concentrations of their zymogen forms. Taken together, we propose that in the 
absence of stress, these zymogens remain at equilibrium between their 
membrane-bound and solution-state species. However, stress triggers the 
release of PS molecules on a membrane surface. At high enough concentrations, 
these PS molecules become tightly packed, which in turn creates more high 
affinity binding sites. As a result, the Kd for membrane binding drops below the 
plasma concentration, and pushes the equilibrium of these proteins towards their 
membrane-bound states. By increasing the affinities of these proteins for 
membranes, PS molecules contribute to increasing the overall density of these 
proteins on the membrane surface, and at the nanoscale level, this increased 
density may be very substantial. Others have proposed that proteins in the 
vicinity of the membrane surface may be orders of magnitude greater than those 
observed in the bulk solution [5]. This high local concentration of proteins within a 
constrained volume may in turn substantially and positively affect prothrombinase 
complex formation and function [30-32]. 
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4.4.2 Prothrombinase Complex Function is Regulated by its Local PS 
Environment 
 
Nanodiscs provide a system in which we can more easily control and 
resolve the phospholipid environment in the immediate vicinity of a protein. To 
determine, at the nanoscale, how prothrombinase is modulated by PS, we 
assembled the complex and its substrate on liposomes or 10.8 nm diameter 
bilayer Nanodiscs and compared their functions. Our experiments show that the 
Km for prothrombinase function on liposomes became optimal at very low PS 
content (10%PS). The Km for prothrombinase function on Nanodiscs, however, 
decreased steadily as more PS molecules were gradually incorporated into the 
bilayer. Only at a very high PS content (70%) did Km values on Nanodiscs 
become equivalent with liposomes containing 10-40%PS. We reason that 
because Nanodiscs prevent long-range recruitment of PS, the immediate vicinity 
of the prothrombinase complex can be effectively titrated with PS molecules as 
PS content is raised. This degree of control, in turn, gives us a more accurate 
description of the actual PS composition in the immediate vicinity of the 
prothrombinase complex. On the other hand, liposomes can contain ~200 times 
more phospholipid molecules than Nanodiscs. Evident from the maximal Km 
values at very low %PS (Fig. 5A), phospholipid domains with optimal PS content 
for activating prothrombin by prothrombinase can effectively form on ~100 nm 
diameter liposomes with as little as 10% PS. Taken together, these results show 
that there an extremely high content of PS is required for maximal 
prothrombinase function. Even with their constrained size, Nanodiscs can 
effectively support the function of the prothrombinase complex if a very high 
 
 
85 
amount of PS in incorporated into the bilayer. This requirement for high PS is 
masked in liposomes because its phospholipid surface has the propensity to form 
domains that extremely rich in PS molecules. 
We have described how the prothrombinase complex can effectively 
assemble and activate its natural protein substrate, prothrombin, on a 
nanometer-scale bilayer that contains only 120 phospholipids molecules per 
leaflet. To generate full function, no less than three proteins are needed to bind 
on the same PS-containing membrane surface. As such, a requisite amount of 
PS incorporated into the membrane is required to bind each protein molecule. 
We have estimated that in order for a single molecule of prothrombin, factor Xa, 
and factor Va to bind membranes with high affinity, approximately 9, 4, and less 
than 24 PS molecules are required for each protein respectively. Taken together, 
these results indicate that approximately 37 PS molecules are required for 
optimal assembly of the prothrombinase complex and its substrate. Although this 
estimate does not take into account interactions that may affect the net amount 
of PS required, it is interesting to note that maximal kcat values for prothrombin by 
prothrombinase on 10.8 nm-diameter bilayer Nanodiscs also occurs between 24-
36 PS molecules (Fig. 4.5D). Compared to liposomes, however, prothrombin 
activation was found to be less efficient on the constrained bilayer of the 
Nanodiscs. A drop in prothrombin turnover rates on Nanodiscs can also be seen 
at very high PS content. Thus, the size and density of anionic phospholipids 
within a membrane can contribute greatly to the efficiency of substrate turnover. 
Indeed, studies prior have shown that mixtures of PC and PS are more effective 
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in promoting thrombin generation than PC or PS membranes alone [33,34]; 
indicating that an optimal amount of PS molecules are required for maximal 
prothrombinase turnover. 
Many blood coagulation serine proteases and their subsequent 
protease:cofactor complexes have evolved binding sites to regulate their 
functions. At the fundamental level, these “exosites” may be anywhere in the 
vicinity of the complex, yet outside its active site. Indeed, in a previous 
manuscript, we described how the extrinsic tenase complex, another membrane-
bound blood coagulation complex, uses anionic phospholipids as exosites to 
enhance the binding affinity of its protein substrates [13]. In a similar manner, we 
propose that the PS molecules located within nanometers of the prothrombinase 
complex serve as an exosite to regulate its assembly and function. 
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4.5 FIGURES 
 
 
 
 
 
Figure 4.1 Schematic of the membrane contact domains of fVa and fXa 
on nanoscale bilayers. The C1 and C2 domains of bovine fVa in blue (PDB file 
1SDD [19]) and the Gla domain of fXa is in cyan (PDB file 1IOD [18]) are placed, 
to scale, on nanoscale bilayers (tan circles) of 7.7 nm diameter (panel A), or 10.8 
nm diameter (panel B).  The 10.8 nm-diameter bilayer appears highly likely to 
have sufficient room to assemble the prothrombinase complex (Va·Xa) and one 
or more substrate molecules.  The smaller 7.7 nm-diameter bilayer seems 
unlikely to support the entire complex and substrate. 
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Figure 4.2 Binding of prothrombin to 7.7 nm-diameter bilayer Nanodiscs 
of varying PS content, measured by surface plasmon resonance. A, steady-
state binding of prothrombin to Nanodiscs of indicated %PS as a function of 
prothrombin concentration. Lines are the single-site ligand binding equation fitted 
to the data. B, Kd values derived from binding isotherms depicted in A, as a 
function of PS content. C, calculated negative free energy change for 
prothrombin bind as a function of PS content (derived from Kd values in B). D, 
The number of prothrombin molecules bound per leaflet at saturating 
prothrombin concentrations, calculated as described in text. Data represent 
mean ± S.E. (n ≥ 3). The upper x axes in B - D represent the calculated number 
of PS molecules per leaflet, whereas the lower x axes are the mol % of PS. 
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Figure 4.3 Binding of fXa and fX to 7.7 nm-diameter bilayer Nanodiscs of 
varying PS content, measured by surface plasmon resonance. A, steady-
state binding of fXa to Nanodiscs of indicated %PS as a function of fXa 
concentration. Lines are the single-site ligand binding equation fitted to the data. 
B, Kd values for fXa (circles, solid line) derived from binding isotherms depicted in 
A, as a function of PS content. Kd values for fX (squares, dotted line) were 
replotted from Shaw et al. [13], and are overlaid here for comparison. C, 
calculated free energy change for fXa and fX binding as a function of PS content 
(derived from Kd values in B, and from Shaw et al. [13]. D, The number of fXa 
and fX molecules bound per Nanodisc leaflet at saturating fX or fXa 
concentrations, calculated as described in text or replotted from Shaw et al., 
2007. Data represent mean ± S.E. (n = 3). The upper x axes in B - D represent 
the calculated number of PS molecules per leaflet, whereas the lower x axes are 
the mol % of PS. 
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Figure 4.4 Binding of fVa to 10.8 nm-diameter bilayer Nanodiscs of 
varying PS content, measured by surface plasmon resonance. A, steady-
state binding of fVa to Nanodiscs of indicated %PS as a function of fVa 
concentration. Lines are the single-site ligand binding equation fitted to the data. 
B, Kd values derived from binding isotherms depicted in A, as a function of PS 
content. C, calculated free energy changes for fVa binding as a function of PS 
content (derived from Kd values in B). D, The number of fVa molecules bound per 
Nanodisc leaflet at saturating fVa concentrations, calculated as described in text. 
Data represent mean ± S.E. (n = 3). The upper x axes in B - D represent the 
calculated number of PS molecules per leaflet, whereas the lower x axes are the 
mol % of PS. 
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Figure 4.5 The local PS environment modulates prothrombin activation 
by prothrombinase. The following kinetic constants were measured for 
prothrombin activation by prothrombinase: Km using liposomes (A) or 10.8 nm-
diameter bilayer Nanodiscs (B); kcat using liposomes (C) or 10.8 nm-diameter 
bilayer Nanodiscs (D); and kcat/Km using liposomes (E) or 10.8 nm-diameter 
bilayer Nanodiscs (F). Data represent mean ± S.E. (n = 3). The upper x axes in 
B, D, and F represent the calculated number of PS molecules/leaflet, with mol % 
of PS indicated on the lower x axes. Under our experimental conditions rates of 
prothrombin activation were essentially undetectable in the absence of 
phospholipids or while using liposomes or Nanodiscs containing 100% PC, 
precluding their inclusion in this figure. 
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CHAPTER 5 
 
CONCLUSIONS 
 
 
5.1 SUMMARY 
 
Blood coagulation requires the membrane assembly of protein complexes 
composed of catalytic and regulatory subunits.  Damaged cells or platelets can 
dramatically influence the catalytic efficiencies of these membrane-bound 
proteases through increased exposure of anionic phospholipids such as PS on 
the outer leaflet of the plasma membrane.  In the presence of Ca2+, PS can 
spontaneously cluster into membrane microdomains upon which phospholipid-
binding proteins may preferentially assemble.  It therefore seems likely that blood 
clotting reactions occur on membrane surfaces containing very high amounts of 
PS in their immediate vicinities, which may result from both Ca2+ and the PS-
binding properties of the proteins themselves.  Thus, local variations in the 
nanoenvironment immediately surrounding these complexes may dramatically 
alter their activities. Unfortunately when using even simple model membranes, it 
is very difficult to define the phospholipid composition immediately surrounding 
these membrane-bound complexes and their substrates.  In particular, when 
using liposomes or other model membranes, this parameter is typically not under 
experimental control. 
For this reason, the membrane composition in the immediate vicinity of 
blood clotting reactions is largely unknown.  I approached this problem by using a 
unique system of stable phospholipid bilayers of defined size as a platform for 
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studying membrane-protein interactions.  These “Nanodiscs” are soluble, 
nanometer-scale bilayers that are encircled and stabilized by a protein called 
MSP.  By assembling the constituent proteins of certain blood clotting complexes 
on these submicroscopic bilayers, the long-range recruitment of anionic 
phospholipids that occurs in larger phospholipid systems such as liposomes can 
be circumvented, and the identity and contribution of the membrane in the direct 
vicinity of these complexes can be more clearly defined. 
Before conducting detailed studies with membrane-bound proteins of 
blood coagulation on Nanodiscs however, it was first necessary to assemble and 
characterize the Nanodisc system.  Secondly, in order to study the initiation of 
blood coagulation by TF, it was also necessary to incorporate TF into the 
Nanodisc bilayer.  Focusing my experiments on Nanodiscs with bilayers having 
diameters of 7.7 and 10.8 nm, my results showed that Nanodiscs with 8 nm-
diameter bilayers contained a mean of 67 ± 1 phospholipid molecules per bilayer 
leaflet and had final proportions of PC and PS that were faithfully preserved 
throughout the assembly process.  Likewise, Nanodiscs with 10.8 nm-diameter 
bilayers were found to contain a mean of 120 ± 4 phospholipid molecules per 
leaflet.  Except for extreme circumstances, Nanodisc species containing PCPS 
bilayers are stable in physiological amounts of Ca2+.  Moreover, active 
membrane-bound TF has been successfully reconstituted into 8 nm-diameter 
Nanodiscs.  These TF-Nanodiscs have a stoichiometry of 1.02 TF molecules per 
Nanodisc and exhibit considerable procoagulant activity.  Overall, these results 
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validate the use of these bilayers as tightly-controlled membrane surfaces upon 
which to control, assemble and study the components of the blood coagulation 
cascade at the nanoscale. 
Using Nanodiscs, I investigated how altering the PS content in the 
immediate environment surrounding the TF·VIIa complex controls the catalytic 
efficiency toward its membrane-binding substrate, fX.  I found that as the PS 
content of the nanobilayers increased, fX bound these membranes in a saturable 
and concentration-dependent manner.  Furthermore, as PS increased, both the 
affinity and the amount of fX bound to these membranes increased concordantly.  
Through the same system, I also showed that full proteolytic activity of the 
TF·VIIa complex requires extremely high local concentrations of anionic 
phospholipids, and furthermore that a large membrane-bound pool of its 
substrate, fX, is not required to support sustained catalysis.  These findings 
provided new insights into the initiation of thrombosis; the event that triggers the 
death of most people. 
Next, I investigated how altering the PS content of the membrane surface 
surrounding Va·Xa complex controls its catalytic efficiency toward its membrane-
binding substrate, prothrombin.  I found that the number of binding sites for 
factors Va, Xa and prothrombin increased almost linearly with the number of PS 
molecules per nanobilayer.  Effects on binding affinity were more complex: Kd 
values for binding of factor Xa or prothrombin to nanobilayers decreased 
monotonically with increasing PS content, while the Kd for factor Va-nanobilayer 
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binding showed a biphasic dependence on PS content. Km for prothrombin 
activation decreased correspondingly as the PS content of nanobilayers 
increased, while kcat exhibited a biphasic dependence on PS content. The kcat/Km 
for prothrombin activation by prothrombinase assembled on nanobilayers 
increased almost linearly with PS content. These results reveal how anionic 
phospholipids in the direct vicinity (i.e., within a few nanometers) of the final 
membrane-bound complex of blood coagulation regulates its assembly and 
function. 
 Many blood coagulation serine proteases and their subsequent 
protease:cofactor complexes have evolved binding sites to regulate their 
functions.  At the fundamental level, these “exosites” may be anywhere in the 
vicinity of the complex, yet by definition lie outside the active site.  In fact, 
exosites may be located on the protease, the protein cofactor, or both.  In this 
project, I have described how the TF·VIIa and Va·Xa complexes use anionic 
phospholipids within their immediate vicinity to mediate the binding affinity of their 
constituent proteins and substrates.  In light of these findings, I propose that the 
PS molecules located within nanometers of these complexes serve as critical 
exosites to regulate their assemblies and function. 
 
5.2 FUTURE DIRECTIONS 
 
5.2.1 Lipid-Mediated Regulation of Blood Coagulation Complexes 
I have demonstrated that the TF·VIIa enzyme complex can efficiently 
activate its natural protein substrate, fX, even when this membrane-bound 
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enzyme complex is confined to a nanoscale lipid bilayer consisting of only ~67 
phospholipid molecules per leaflet (Fig. 3.4).  My results with TF-liposomes have 
showed that kcat values increased as the percentage of PS was elevated, 
paralleling the PS dependence of fX binding to Nanodiscs (Fig. 3.2B).  At very 
high concentrations of PS, however, TF-Nanodiscs did not exhibit this behavior.  
Instead, when the PS composition in Nanodiscs was raised to an extremely high 
amount, product turnover slowed.  Notably, this phenomenon also occurs with 
the Va·Xa complex (see Fig 4.5). 
Hathcock et al., [1,2], have proposed that removal of product (fXa) from 
the vicinity of the TF:VIIa complex by lateral diffusion on the membrane surface is 
likely the rate-limiting process controlling the apparent kcat  of this reaction.  It can 
be further speculated that this same mechanism may be occurring with the Va·Xa 
complex as well.  It is possible that product removal from these membrane-bound 
blood coagulation complexes may be less effective when they are constrained 
within nanoscale bilayers, and especially when the PS composition of the bilayer 
is very high. 
This unusual phenomenon may be because the tiny membrane surface 
within the Nanodisc must rely on continuous binding of membrane-bound 
substrate to, and dissociation of membrane-bound product from the nanobilayer 
to allow sustained rates of substrate activation.  Turnover of substrate is 
therefore dependent upon dissociation of product from the membrane in order to 
provide room for new substrate molecules to bind within a few nm of the blood 
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coagulation protein complex.  As the PS composition of the nanobilayer 
increases, however, so do the binding affinities of substrates and products for the 
membrane surface.  Moreover, if the product has a higher affinity for PS 
membranes compared to the substrate, the product may effectively inhibit this 
reaction. 
Investigating if the nascent product of these complexes competitively 
inhibits the catalysis of their respective substrates may yield additional insight as 
to how the blood coagulation cascade is regulated.  Through the Nanodisc 
system, TF·VIIa or Va·Xa-catalyzed reactions can be finely examined as a 
function of bilayer size and PS content at a level never before seen.  Using, for 
example, a product of the respective reactions as a competitor to inhibit or rescue 
the turnover rate of the enzyme-cofactor complex.  The use of stopped-flow may 
also be valuable to further investigate rate of substrate association and product 
dissociation to and from these membrane complexes. 
 
5.2.2 Phosphatidylethanolamine-Mediated Enhancement of Clotting Factor 
Activity 
 
 To great effect, many in vitro studies involving blood coagulation 
complexes have used mixtures of net neutral and anionic phospholipids in 
liposome-based systems that recapitulate the stimulatory effects of their natural 
counterparts (e.g., activated platelets and damaged endothelial cells).  Notably, 
PS is accepted as the most effective surface in supporting catalysis [3].  Studies 
by the Morrissey group have subsequently demonstrated that 
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phosphatidylethnolamine (PE) can synergize with low levels of PS to promote fX 
activation by the TF·VIIa complex comparable to liposomal preparations that 
have much higher PS content [4].  The mechanism for this synergy is not 
incompletely understood and notably applies not only to TF·VIIa, but to other 
membrane-bound complexes of blood coagulation.   
One hypothesis for this phenomenon is that due to its tendency to produce 
hexagonal-shaped bilayers, PE may induce the clustering of PS microdomains 
on liposomal surfaces.  As such, this phenomenon promotes more efficient 
substrate utilization from membrane-bound blood coagulation complexes.  Since 
Nanodiscs are such small bilayers, they may essentially represent membrane 
microdomains themselves, rendering PE-induced clustering of PS unlikely.  
When comparing the PSPE-dependence of fX activation by TF·VIIa on 
Nanodiscs and liposomes, absence of PSPE synergy in Nanodiscs may support 
to this idea.  An alternate hypothesis is that PE, along with PS, represents yet 
another binding site for membrane-binding procoagulant proteins.  As such, if 
synergy is indeed present in PEPS-containing Nanodiscs, the effect of PE on the 
binding affinity of the component clotting factors to Nanodiscs may be measured 
via SPR and other binding experiments.  These experiments can be further 
expanded to other natural phospholipids, such as phosphatidylinositol and 
phosphatidylglycerol, which have been found to affect the function of blood 
clotting proteins. 
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5.2.3 Assembly and Function of Other Membrane-Bound Hemostatic 
Complexes on Nanodiscs 
 
Through this project, I have shown that Nanodiscs provide a bilayer of 
defined size and phospholipid composition that may be effectively used as an 
experimental membrane surface upon which to assemble and study the 
components of both the TF·VIIa and Va·Xa complexes.  A logical expansion of 
this work is to investigate other membrane-bound protease complexes involved 
in hemostasis.  Two notable candidates are the intrinsic tenase and the 
thrombin·thrombomodulin complexes.  The intrinsic tenase complex is another 
physiological activator of fX.  It is composed of the serine protease factor IXa 
(fIXa), and its protein cofactor factor VIIIa (fVIIIa).  fIXa is yet another vitamin K 
dependent serine protease (much like fVIIa and fXa), and fVIIIa greatly 
resembles fVa in structure and function.  The thrombin-thrombomodulin complex, 
on the other hand, activates a serine protease zymogen called protein C, 
ultimately leading to clot dissolution.  Notably, thrombomodulin is an integral 
membrane protein like TF and must be incorporated into a suitable membrane for 
optimal activity.  Experiments concerning these complexes may be conducted in 
a manner very similar to the present work, but should take account the different 
properties of the constituent proteins involved in each complex. 
 
5.2.4 TF-Nanodiscs as Therapeutic Hemostatic Agents. 
TF embedded within Nanodiscs (TF-Nanodiscs) demonstrated appreciable 
procoagulant activity.  Moreover, it was found that the composition of the 
phospholipid membrane in the immediate vicinity of TF (and other procoagulant 
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proteins) can dramatically influence its function.  In many ways, these results 
provide greater insight into how the initiation of blood coagulation may be 
induced and controlled both in vitro and in vivo.  A natural extension of this 
project may therefore be the development and application of TF-Nanodiscs of 
superior solubility and stability for the delivery of TF.  Clinically, TF-Nanodiscs 
could function as novel, highly potent hemostatic agents and tumor-targeting 
agents. 
The physical properties of the Nanodisc itself make it an excellent 
candidate for in vivo protein delivery.  For instance, because they were originally 
derived from and resemble natural lipoproteins in the body, Nanodiscs may 
demonstrate reduced toxicity and immunoreactivity.  Their readily modifiable 
structural properties could enable the attachment of targeting molecules or of 
solid supports to the MSP, the phospholipid bilayer, or directly on TF itself.  
Moreover, their small size may enable diffusion through small capillaries that 
larger particles cannot otherwise traverse, and their homogeneity may aid in 
ensuring controlled dosages.  Nanodiscs can furthermore be inexpensively 
produced in large quantities and in a relatively short amount of time. 
Existing hemostatic agents for the cessation of excessive bleeding are 
generally composed of formulations that are weak activators of blood 
coagulation.  Presently, collagen and oxidized cellulose are commonly used in 
surgery to prevent bleeding [5,6].  These formulations work as hemostatic agents 
by promoting the activation of platelets, and are often supplemented with 
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thrombin.  However, as one of the last enzymes in the blood clotting cascade, 
thrombin must be used in very high concentrations.  Fibrin sealants composed of 
fibrinogen and thrombin are also commonly used [7].  These processes invariably 
take advantage of the latter part of the procoagulant pathway, and are inefficient 
initiators of blood coagulation.  On the other hand, membrane-bound TF is the 
strongest activator of the blood coagulation cascade, and TF-Nanodiscs exhibit 
considerable procoagulant activity.  As such, for treatment of excessive bleeding 
due to surgery, trauma, or deficiencies in the clotting system, TF-Nanodiscs may 
represent superior formulations for inducing the cessation of blood loss.  
Additionally, the scaffold protein of TF-Nanodiscs may be crosslinked and 
immobilized onto a solid support such as collagen or Dacron.  This will prevent 
TF from migrating freely or being washed away by hemorrhaging blood, thereby 
increasing the local concentration of TF at the desired site. 
Solid tumors induce angiogenesis in order to sustain their rapid growth.  
The infarction of tumor vasculature can effectively destroy many critical, blood-
dependent layers of a tumor.  Therefore, antivascular therapy for the targeting 
and infarction of tumors has been a very promising research topic for many 
years.  The delivery of non-membrane bound, soluble TF (sTF) to the vascular 
bed of tumors, for example, has been tested in a variety of model studies [8-11].  
Since it is missing a suitable membrane surface, however, sTF contains activity 
that is orders of magnitude less than membrane-bound TF.  TF-Nanodiscs may 
potentially have superior efficacy for the infarction of tumors.  For future work on 
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vascular tumor delivery of TF-Nanodiscs, an improved formulation of TF-
Nanodiscs with optimized enzymatic activity may be made.  For vascular 
targeting, a fusion protein containing, for example, the ED-B domain of 
fibronectin may be attached to TF and inserted into Nanodiscs.  The ED-B 
domain is a marker for tumoral vasculature expressed in the majority of 
aggressive solid tumors but is undetectable in normal tissues.  TF-Nanodiscs 
containing the ED-B domain may therefore be used to target tumor vasculature in 
experimental mice.  As the amino acid sequence of ED-B is identical in mice, 
rats, dogs, and humans [11], it is an excellent initial candidate for interspecies 
experiments that may eventually culminate in studies in humans.   
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